



# **The 9th U.S.-China Health Summit Building A Sustainable Health Care System & Health Care Innovation & Investment Forum**

**第九届中美健康峰会  
建立可持续发展的卫生健康体系  
暨 医疗健康创新与投融资论坛**

**美国波士顿**

**September 26-27, 2019**

**Joseph B. Martin Conference Center  
Harvard Medical School  
77 Avenue Louis Pasteur, Boston, MA 02115**

**[www.uschinahealthsummit.org](http://www.uschinahealthsummit.org)**

- 1 Welcome Letter 欢迎辞
- 2 Milestone 峰会里程碑
- 4 Agenda 会议议程
- 15 Speakers 嘉宾简介
- 46 Sponsorship 赞助
- 51 Partnership 合作伙伴



Dear friends:

On behalf of the Summit Organizing Committee, we sincerely thank you for joining us at the 9th U.S.- China Health Summit in Boston!

Since its inauguration in 2011 at Harvard University, the annual U.S.-China Health Summit has taken place alternately in the U.S. and in China. It started and still serves as the major platform for the “meeting of great minds” from these two countries to examine the progress and challenges of healthcare reform. Over the past eight years, the common goal remains unchanged. As the two global giants seek ways to extend access, improve quality, and lower the cost of care for their citizens, we exchange information and good practices on each other’s efforts. Other topics we’ve examined in the past include public health, caring for aging population, precision medicine, mental health, and life course health for women and children.

As the new healthcare reform in China enters its 10th year journey and the Affordable Care Act (ACA) moves on into the 9th year, we come together again to review and discuss existing and emerging new challenges and opportunities. Today, we are also at an important crossroad. While we have seen unprecedented science and technology advancement which have the potential to save millions of lives, we are also facing huge threats to human survival such as global warming, escalated medical costs and socio-economic instability. How to invest in healthcare innovation more effectively and how to build sustainable health care systems are the major themes of the summit this year.

We are inspired by the open dialogue, mutual learning and continuing collaboration among many sectors—ranging from thought leaders, traditional and emerging industry leaders, healthcare providers, to financial investors and insurance payers from both countries—as we engage in the two-day discussions on science, innovation, technology, IP protection, service delivery and payment models.

Healthcare is a basic human right. We strongly believe that this “meeting of innovative minds” will benefit not only the two great countries but also the rest of the world. We hope you all enjoy the talks and panel discussions, meeting old friends and building new networks. We also encourage you to continue to engage and support the ongoing dialogue and collaboration for the sake of a better, healthier and more sustainable world!

Jing Ma, M.D., Ph.D.  
President & Secretary-General  
U.S.-China Health Summit

MILESTONE 峰会里程碑

Signing of the 2nd Memorandum of Understanding  
中国卫计委与哈佛大学陈曾熙公共卫生学院签署第二轮合作备忘录



2011

September | Boston, U.S.  
1st U.S.-China Health Summit  
九月 | 美国 波士顿  
首届中美健康峰会



October | Boston, U.S.  
3rd U.S.-China Health Summit  
十月 | 美国 波士顿  
第三届中美健康峰会



2012

October | Beijing, China  
2nd U.S.-China Health Summit  
十月 | 中国 北京  
第二届中美健康峰会



Signing of the 3rd Memorandum of Understanding  
中国卫计委与哈佛大学陈曾熙公共卫生学院签署第三轮合作备忘录



2013

U.S.-China Health Summit Inc. established as an NGO  
“中美健康峰会”作为非营利组织正式成立



September | Xi'an, China  
6th U.S.-China Health Summit  
九月 | 中国 西安  
第六届中美健康峰会



2014

October | Nanjing, China  
4th U.S.-China Health Summit  
十月 | 中国 南京  
第四届中美健康峰会



September | Boston, U.S.  
7th U.S.-China Health Summit  
九月 | 美国 波士顿  
第七届中美健康峰会



2015

September | Boston, U.S.  
5th U.S.-China Health Summit  
九月 | 美国 波士顿  
第五届中美健康峰会



October | Chengdu, China  
8th U.S.-China Health Summit  
十月 | 中国 成都  
第八届中美健康峰会



2016

September | Beijing, China  
7th U.S.-China Health Summit  
九月 | 中国 北京  
第七届中美健康峰会



November | Wuhan, China  
9th U.S.-China Health Summit  
十一月 | 中国 武汉  
第九届中美健康峰会



2017

September | Boston, U.S.  
9th U.S.-China Health Summit  
九月 | 美国 波士顿  
第九届中美健康峰会



DAY ONE AGENDA

Health Care Innovation & Investment Forum

Time	Agenda
7:00 am - 8:00 am	Registration
8:00 am - 8:30 am	<b>Opening Remarks</b> <ul style="list-style-type: none"><li>Jing Ma, President &amp; Secretary-General, U.S.-China Health Summit</li><li>William Haseltine, Chairman, U.S.-China Health Summit; Chairman and President, Access Health International</li></ul>
8:30 am - 9:00 am	<b>Session One Keynote: Cost Innovation, Preventing Rare &amp; Common Diseases</b> George Church, Professor of Genetics, Harvard Medical School
9:00 am - 10:00 am	<b>Session One Panel: New Frontier in Precision Medicine</b> Moderator: Antonio Regalado, Senior Editor for Biomedicine, MIT Technology Review Panelists: <ul style="list-style-type: none"><li>George Church, Professor of Genetics, Harvard Medical School</li><li>Peter Fong, Senior Principal, Flagship Pioneering</li><li>Xin He, Founder and Managing Partner, Hyfinity Fund</li><li>Alex Wu, Partner, Green Pine Capital Partners</li></ul>
10:00 am - 10:15 am	Coffee Break
10:15 am - 11:15 am	<b>Session One Showcase: Cell and Gene Therapy</b> Moderator: Michael Fenn, Director, Healthcare & Life Science, Harvard Innovation Labs Panelists: <ul style="list-style-type: none"><li>Luhan Yang, Founder &amp; CEO, Qihan Bio; Co-founder &amp; CSO, eGenesis</li><li>Marilyn X. Zhou, CEO, Guangzhou Double Bioproduct</li><li>Armon Sharei, Founder &amp; CEO, SQZ Biotech</li><li>Lan Cao, Senior Director, Head of Product Development &amp; Global Program Leader, Cell Therapy, Takeda</li></ul>

Time	Agenda
11:15 am - 12:15 pm	<b>Special Dialogue: IP Protection of Regulated Biopharma Innovations</b> Moderator: Sally Wang, Biopharma & Health Tech Executive and Lawyer; General Counsel, U.S.-China Health Summit Panelists: <ul style="list-style-type: none"><li>Jeffrey J. Ellison, Partner, Clark+Elbing</li><li>Can Cui, Associate, Morrison Foerster</li><li>Jonathan Darrow, Assistant Professor, Program on Regulation, Therapeutics &amp; Law, Harvard Medical School</li></ul>
12:30 pm - 1:30 pm	<b>Lunch Talk: Potential Implications of A Decoupling for US High-Tech Industry</b> Yasheng Huang, PhD, Associate Dean and Professor, MIT Sloan School of Management
1:30 pm - 2:00 pm	<b>Session Two Keynote: Learning to Fly: Building A New Model of Person-Centered Primary Care</b> Rushika Fernandopulle, Co-founder & CEO, Iora Health
2:00 pm - 3:00 pm	<b>Session Two Panel: Who Pays for Innovation?</b> Moderator: Rushika Fernandopulle, Co-founder & CEO, Iora Health Panelists: <ul style="list-style-type: none"><li>Michael Greeley, Partner, Flare Capital</li><li>Beth Bierbower, Segment President, Humana</li><li>Stephen Knight, President and Managing Partner, F-Prime Capital</li><li>Kevin Xie, President, Fosun Healthcare Holdings; U.S. Executive Chief Representative, Fosun Group</li><li>Tiger Tang, Co-founder &amp; CEO, iBridge TT International Ltd.</li></ul>
3:00 pm - 3:15 pm	Coffee Break
3:15 pm - 3:45 pm	<b>Session Three Keynote: Digital Therapeutics Revolutionize Healthcare</b> Corey McCann, Founder and CEO of Pear Therapeutics

DAY ONE AGENDA

Health Care Innovation & Investment Forum

Time	Agenda
3:45 pm - 4:45 pm	<b>Session Three Panel: How Digital Health is Transforming Heathcare</b> Moderator: David Mou, Co-founder and Chief Medical Officer, Valera Health; Psychiatrist at Massachusetts General Hospital Panelists: <ul style="list-style-type: none"><li>Corey McCann, Founder and CEO, Pear Therapeutics</li><li>Ligang Zhang, Founder, Chairman &amp; CEO, iKang Health</li><li>Joseph Kvedar, Vice President, Connected Health, Partners Healthcare</li><li>Lingyun Su, Former Director, AliHealth Research Institute</li></ul>
4:45 pm - 5:45 pm	<b>Session Three Showcase: Digital Health Technology is Transforming Healthcare Delivery</b> Moderator: Rick Williams, Former President, Boston Harvard Business School Alumni Association; Managing Director, William Advisory Partners Panelists: <ul style="list-style-type: none"><li>Debra Bass, Global CMO &amp; U.S. President, Nuvo Cares</li><li>Rich Gliklich, Founder &amp; CEO, OM1</li><li>Kuldeep Singh Rajput, Founder &amp; CEO, Biofourmis</li><li>Matt Deng, CEO, Infervision North America</li></ul>
5:45 pm - 6:15 pm	<b>Closing Keynote:</b> Stephen Kennedy Smith, Principal and Board Member of Park Agency Enterprises, Kennedy Family Office  Introduced by: Clement Dai, Special Assistant to Stephen Kennedy Smith
6:15 pm - 7:00 pm	<b>Social Time</b>
7:00 pm - 8:30 pm	<b>VIP Dinner</b>

DAY TWO AGENDA

The 9th Annual Summit - Building A Sustainable Health Care System

Time	Agenda
7:00 am - 8:00 am	<b>Registration</b>
8:00 am - 10:00 am	<b>Session One: Learning &amp; Comparing Health Systems Across Countries &amp; Institutions</b> Opening & Moderators: <ul style="list-style-type: none"><li>Yuanli Liu, Dean, School of Public Health, CAMS &amp; Peking Union Medical College (PUMC)</li><li>Mark A. Davis, Vice President of Brigham Health International, Executive Director of Business Development and Strategic Initiatives, Brigham Health</li></ul> Distinguished Speakers: <ul style="list-style-type: none"><li>Lincoln Chen, President, China Medical Board</li><li>Qizhu Tang, Vice President, Wuhan University; Dean, Wuhan University Medical School; President, Hubei Provincial People's Hospital</li></ul> Keynote Speakers: <ul style="list-style-type: none"><li>Richard Platt, Professor and Chair, Department of Population Medicine, Harvard Medical School &amp; Director, Harvard Pilgrim Health Care Institute</li><li>Daniel Tsai, Assistant Secretary for MassHealth and Medicaid Director for the Commonwealth</li></ul>
10:00 am - 10:30 am	<b>Coffee Break</b>
10:30 am - 12:30 pm	<b>Session Two: Building A Sustainable &amp; Integrated Health Care System</b> Moderator: Gordon Moore, Professor, Department of Population Medicine, HMS Speakers: <ul style="list-style-type: none"><li>Donald Berwick, President Emeritus &amp; Senior Fellow, Institute for Healthcare Improvement</li><li>Yuanli Liu, Dean, School of Public Health, CAMS &amp; Peking Union Medical College</li><li>William Haseltine, Chairman and President, Access Health International; Chairman, U.S.-China Health Summit</li><li>Erdan Huang, Deputy Director, Research Department of Health Service System, Health Development Research Center, National Health Commission of China</li><li>Jianqin Gu, Vice President, Henan Provincial People's Hospital, China</li></ul>

Time	Agenda
12:30 pm - 2:00 pm	<b>Session Three: Lunch Time Dialogue: U.S.-China Relationship: Where Shall We Go?</b> Introduced by: Yuanli Liu; Sally Wang Liang Speakers: <ul style="list-style-type: none"><li>• Ezra Vogel, Henry Ford II Professor of the Social Sciences Emeritus, Harvard University</li><li>• Mark Wu, Henry L. Stimson Professor, Harvard Law School</li></ul>
2:00 pm - 4:00 pm	<b>Session Four: Value-Based Insurance and Healthcare Quality</b> Moderator and speaker: James Frank Wharam, Chief, Division of Health Policy & Insurance, Department of Population Medicine, Harvard Medical School Speakers: <ul style="list-style-type: none"><li>• Shaoping Deng, President, Sichuan Academy of Medical Science &amp; Sichuan Provincial People's Hospital</li><li>• Mark Fendrick, Director, Value-Based Insurance Design (V-BID) Center, University of Michigan</li><li>• Michael Sherman, Chief Medical Officer, Harvard Pilgrim Health Care</li><li>• Yong Xu, President, Shenzhen People's Hospital, China</li><li>• David Khougazian, Head of Specialty Care for China and Emerging Market, Sanofi</li></ul>
4:00 pm - 4:15 pm	<b>Coffee Break</b>
4:15 pm -5:15 pm	<b>Session Five: Round Table - Future Public Health &amp; Healthcare in China</b> Speaker & Moderator: Aiping Yang, Director, Center for Capacity Building & Continue Education, National Health Commission of China Panelists: <ul style="list-style-type: none"><li>• Huan Xi, Vice President, Beijing Hospital, China</li><li>• Qingyu Kong, Vice President, Beijing Anzhen Hospital, Capital Medical University</li><li>• Mei Xu, President, Yunnan Richland Hospital</li><li>• Tao Hong, Vice President, 1st Teaching Hospital, Nanchang University</li></ul>

Time	Agenda
5:15 pm - 6:15 pm	<b>Session Six: Round table - Future Public Health &amp; Healthcare in the U.S.</b> Speaker & Moderator: Arlene Bierman, Director of Center for Evidence and Practice Improvement (CEPI), Agency for Healthcare Research and Quality (AHRQ), U.S. DHHS Panelists: <ul style="list-style-type: none"><li>• Joe Kimura, CMO, Atrius Health</li><li>• Marc-David Munk, Former Chief Medical Officer, CVS Minute Clinic</li><li>• Christine Lu, Associate Professor &amp; Co-director, PRecisiOn Medicine Translational Research (PROMoTeR) Center, Department of Populatin Medicine, HMS &amp; HPHCI</li><li>• Alfred Demaria, Former State Epidemiologist for Massachusetts and former Medical Director of the Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health</li></ul>
6:15 pm - 6:30 pm	<b>Closing Remarks</b>



第一天会议议程

医疗健康创新与投融资论坛

时间	日程
7:00 am - 8:00 am	注册签到
8:00 am - 8:30 am	<b>开幕辞</b> <ul style="list-style-type: none"><li>马晶, 中美健康峰会主席兼秘书长</li><li>William Haseltine, 中美健康峰会理事长, Access Health 主席</li></ul>
8:30 am - 9:00 am	<b>论坛一：主旨演讲 – 成本创新，预防罕见及常见病</b> 演讲嘉宾：George Church, 哈佛医学院遗传学教授
9:00 am - 10:00 am	<b>论坛一：圆桌讨论 – 精准医学的新前沿</b> 主持人：Antonio Regalado, 《麻省理工科技评论》生物医药资深主编 讨论嘉宾 <ul style="list-style-type: none"><li>George Church, 哈佛医学院遗传学教授</li><li>Peter Fong, Flagship Pioneering 高级主管</li><li>何欣, 汇鼎投资创始人及管理合伙人</li><li>Alex Wu, 松禾资本合伙人</li></ul>
10:00 am - 10:15 am	茶歇
10:15 am - 11:15 am	<b>论坛一: 创新展示 – 细胞治疗与基因治疗</b> 主持人：Michael Fenn, 哈佛创新实验室健康与生命科学主任 讨论嘉宾 <ul style="list-style-type: none"><li>杨璐菡, 启函生物创始人兼首席执行官; eGenesis 联合创始人兼首席科学官</li><li>周晓鸿, 广州达博生物制品有限公司首席执行官</li><li>Armon Sharei, SQZ Biotech 创始人兼首席执行官</li><li>Lan Cao, 武田药品细胞治疗资深主管</li></ul>

时间	日程
11:15 am - 12:15 pm	<b>特别论坛：生物制药创新的知识产权保护与监管</b> 主持人：梁王渊恒（Sally Wang），健康科技与生物制药企业家律师; 中美健康峰会法律总顾问 讨论嘉宾 <ul style="list-style-type: none"><li>Jeffrey J. Ellison, Clark+Elbing 合伙人</li><li>崔燊, 美富律师事务所律师</li><li>Jonathan Darrow, 哈佛医学院政策、治疗与法律中心助理教授</li></ul>
12:30 pm - 1:30 pm	<b>午餐会：中美脱钩对美国高新技术产业的影响</b> 黄亚生, MIT Sloan 商学院副院长、教授
1:30 pm - 2:00 pm	<b>论坛二: 主旨演讲 – 学会飞翔：构建以人为本的新型初级医疗</b> Rushika Fernandopulle, Iora Health 创始人兼首席执行官
2:00 pm - 3:00 pm	<b>论坛二：圆桌讨论 – 谁为创新买单？</b> 主持人：Rushika Fernandopulle 讨论嘉宾 <ul style="list-style-type: none"><li>Michael Greeley, Flare Capital 合伙人</li><li>Beth Bierbower, Humana 保险副总裁</li><li>Stephen Knight, F-Prime Capital 主席与管理合伙人</li><li>谢懿立Kevin, 复星健康控股总裁, 纽约办公室执行首席代表</li><li>汤敏超Tiger, 易创科技国际有限公司联合创始人、首席执行官</li></ul>
3:00 pm - 3:15 pm	茶歇
3:15 pm - 3:45 pm	<b>论坛三：主旨演讲 – 数字化处方方法引领医疗变革</b> 演讲嘉宾：Corey McCann, Pear Therapeutics 创始人兼首席执行官

第一天会议议程

医疗健康创新与投融资论坛

时间	日程
	<b>论坛三：圆桌讨论 – 智慧医疗，以合理的成本提供高质量的服务</b> 主持人：David Mou, Valera Health 联合创始人及医疗总监；麻省总医院精神科医生 讨论嘉宾 <ul style="list-style-type: none"><li>Corey McCann, Pear Therapeutics 创始人兼首席执行官</li><li>张黎刚, 爱康国宾创始人、董事长兼首席执行官</li><li>Joseph Kvedar, Connected Health, Partners Healthcare 副总裁</li><li>苏凌云, 阿里健康研究院前院长</li></ul>
3:45 pm - 4:45 pm	
	<b>论坛三：创新展示 – 智慧医疗变革医疗服务模式</b> 主持人：Rick Williams, 哈佛商学院校友会（波士顿地区）前主席；William Advisory Partners 创始人兼总经理 讨论嘉宾 <ul style="list-style-type: none"><li>Debra Bass, Nuvo Cares 首席医疗官及美国区域总裁</li><li>Richard Gliklich, OM1 创始人及首席营销官</li><li>Kuldeep Singh Rajput, Biofourmis 创始人及首席执行官</li><li>邓昱枫, 推想科技北美首席执行官</li></ul>
4:45 pm - 5:45 pm	
5:45 pm - 6:15 pm	<b>主旨演讲：相互依存时代下的医疗健康</b> Stephen Kennedy Smith, 肯尼迪家族办公室 Park Agency Enterprises 董事  嘉宾介绍：戴华, Stephen Kennedy Smith 特别助理
6:15 pm - 7:00 pm	<b>社交活动</b>
7:00 pm - 8:30 pm	<b>VIP晚宴</b>

第二天会议议程

中美健康峰会 – 建立可持续发展的卫生健康体系

时间	日程
7:00 am - 8:00 am	<b>注册签到</b>
8:00 am - 10:00 am	<b>论坛一：卫生体系与医疗机构间的学习与比较</b> 主持人： <ul style="list-style-type: none"><li>刘远立, 中国医学科学院–北京协和医学院公共卫生学院院长</li><li>Mark A. Davis, 布莱根健康国际副总监；布莱根健康合作发展与战略计划执行总监</li></ul> 特别演讲嘉宾 <ul style="list-style-type: none"><li>陈致和 (Lincoln Chen), 美国中华医学基金会主席</li><li>唐其柱, 武汉大学副校长；湖北省人民医院院长</li></ul> 主旨演讲嘉宾 <ul style="list-style-type: none"><li>Richard Platt, 哈佛大学医学院人群医学系系主任</li><li>Daniel Tsai, 麻省健保计划 (MassHealth) 助理部长兼联邦医疗补助计划主任</li></ul>
10:00 am - 10:30 am	<b>茶歇</b>
10:30 am - 12:30 pm	<b>论坛二：建立可持续发展的整合型医疗卫生体系</b> 主持人：Gordon Moore, 哈佛医学院人群医学系教授 演讲嘉宾 <ul style="list-style-type: none"><li>William Haseltine, 中美健康峰会理事长；Access Health 创始人兼主席</li><li>刘远立, 中国医学科学院–北京协和医学院公共卫生学院院长</li><li>Donald M. Berwick, 美国医疗保健改善研究院 (IH) 荣休主席</li><li>黄二丹, 中国国家卫健委卫生发展研究中心卫生服务体系研究部副部长</li><li>顾建钦, 中国河南省人民医院副院长</li></ul>
12:30 pm - 2:00 pm	<b>论坛三：午餐讨论 – 中美关系何去何从？</b> 嘉宾介绍: 刘远立, 梁王渊恒 演讲嘉宾 <ul style="list-style-type: none"><li>傅高义 (Ezra Vogel), 哈佛大学社会科学荣休教授, 东亚问题知名学者</li><li>伍人英 (Mark Wu), 哈佛大学法学院 Henry L. Stimson 教授</li></ul>



时间	日程
2:00 pm - 4:00 pm	<b>论坛四：价值医疗保险与医疗服务</b> 主持与演讲嘉宾: James Frank Wharam, 哈佛大学医学院人群医学系医疗政策与保险部主任 演讲嘉宾: <ul style="list-style-type: none"><li>· 邓绍平, 四川省医学科学院、四川省人民医院院长</li><li>· Mark Fendrick, 密歇根大学基于价值保险设计中心 (V-BID) 主任</li><li>· Michael Sherman, 哈佛 Pilgrim 医疗研究所首席医疗官</li><li>· 徐勇, 深圳市人民医院书记</li><li>· David Khougazian, 赛诺菲中国与新兴市场孤儿药与特殊药品总负责人</li></ul>
4:00 pm - 4:15 pm	<b>茶歇</b>
4:15 pm - 5:15 pm	<b>论坛五：圆桌讨论 – 中国公共卫生与医疗服务的未来</b> 演讲与主持: 杨爱平, 中国国家卫健委能力建设与继续教育中心主任 论坛嘉宾: <ul style="list-style-type: none"><li>· 奚桓, 北京医院副院长</li><li>· 孔晴宇, 首都医科大学北京安贞医院副院长</li><li>· 徐梅, 云南瑞奇德医院院长</li><li>· 洪涛, 南昌大学第一附属医院副院长</li></ul>
5:15 pm - 6:15 pm	<b>论坛六：圆桌讨论 – 美国公共卫生与医疗服务的未来</b> 演讲嘉宾与主持人: Arlene Bierman, 美国卫生及公共服务部医疗研究与质量局(AHRQ) 证据与实践改进中心主任 论坛嘉宾: <ul style="list-style-type: none"><li>· Marc–David Munk, CVS Minute Clinic 前首席医疗官</li><li>· Christine Lu, 哈佛医学院人群医学系精准医学研究中心主任及副教授</li><li>· Joe Kimura, Atrius Health 社区医疗联盟首席医疗官</li><li>· Alfred Demaria, 麻州公共卫生署传染病局医学主任、麻州首席流行病学家</li></ul>
6:15 pm - 6:30 pm	<b>闭幕式</b>

## Speakers & Moderators 嘉宾简介 – DAY ONE




### Jing Ma 马晶

President & Secretary-General, U.S.-China Health Summit

中美健康峰会主席兼秘书长

Together with Dr. Yuanli Liu, Dean of School of Public Health, Peking Union Medical College, Dr. Ma co-established the U.S.-China Health Summit in 2011, which has been alternated between U.S. and China annually. It becomes the major platform for exchanging ideas, communication and collaboration among top leaders in academia, medical services, policy makers and healthcare industries between the two countries. In 2018, Dr. Ma created the China Center at the Department of Population Health, Harvard Medical School and Harvard Pilgrim Health Care Institute and serves as the founding Director.

马教授和协和医学院公共卫生学院院长刘远立院长于2011年在哈佛大学共同创建了中美健康峰会，至此年度峰会轮流在中美两国举办，已成为中美两国间在健康医疗领域产、学、研、政、商的高端交流与合作平台。2018年，马教授创建了哈佛大学医学院人群医学系–哈佛朝圣健康保险研究院的“中国中心”并担任创始主任。马教授及团队对接国际国内资源，探索“以人为本、主动健康、整合医疗、连续服务”的创新型医疗服务与全生命周期人群健康模式。



### William Haseltine

Chairman, U.S.-China Health Summit 中美健康峰会主席

Chairman and President, Access Health International Access Health主席

William A. Haseltine, PhD, was a professor at Harvard Medical School and Harvard School of Public Health from 1976 to 1993 where he was founder and chair of the Division of Biochemical Pharmacology and the Division of Human Retrovirology. He is well known for his pioneering work on cancer, HIV/AIDS, and genomics. He has authored more than two hundred manuscripts in peer reviewed journals. He is the founder of Human Genome Sciences, Inc., and served as the chairman and CEO of the company for 12 years. Dr. William Haseltine was listed by Time Magazine as one of the world's 25 most influential business people in 2001 and one of the 100 most influential leaders in biotechnology by Scientific American in 2015.

1976年到1993年，William Haseltine 博士在哈佛医学院和哈佛大学公共卫生学院担任教授，创立并主持了生化药理学部门及人类逆转录病毒学部门。他被公认为癌症、艾滋病、基因组学领域的专家。他创立了人类基因组科学股份有限公司，担任董事长兼CEO职位12年。2001年，威廉哈兹尔廷博士被《时代》杂志评选为世界最具影响力的25位商界人士之一。2015年，威廉哈兹尔廷博士被《科学美国人》评为世界生物科技最具影响力的100位领袖之一。



## George Church

Professor of Genetics, Harvard Medical School

哈佛医学院遗传学教授

George Church is Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org, which provides the world's only open-access information on human Genomic, Environmental & Trait data (GET). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, *Helicobacter pylori*) in 1994. His innovations have contributed to nearly all “next generation” DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Na-nopore). This plus his lab's work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics ) & synthetic biology / therapeutics ( Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive ).

George Church 是哈佛医学院的遗传学教授以及全球唯一的综合人类基因组、环境和表型数据的开源信息平台PersonalGenomes.org的主任。他于1984年博士毕业，期间的研究包括首次直接基因组测序方法，分子多重测序和条形码技术。这些技术应用于1994年的第一个全基因组（病原微生物*Helicobacter pylori*）的测序。几乎所有的“下一代DNA测序”技术和公司(CGI-BGI, Life, Illumina, Nanopore)都基于他的创新研究。此外，其实验室在基于芯片的DNA合成、基因编辑和干细胞工程相关领域的工作直接促成了一系列生物技术公司的诞生，包括诸如医疗诊断方向的公司(Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics) 和合成生物学/基因治疗方向的公司( Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive)。他同时还是新的隐私保护、生物安全、伦理法规和社会影响、环境和生物安全政策的先驱。



## Antonio Regalado

Senior Editor for Biomedicine, MIT Technology Review

《麻省理工科技评论》生物医学资深主编

Antonio Regalado is the editor for biomedicine for MIT Technology Review. He looks for stories about how technology is changing medicine and biomedical research. Before joining MIT Technology Review in July 2011, Regalado lived in São Paulo, Brazil, where he wrote about science, technology, and politics in Latin America for Science and other publications. From 2000 to 2009, he was the science reporter at the Wall Street Journal and later a foreign correspondent.

Antonio Regalado 是《麻省理工科技评论》的生物医学编辑。他致力于挖掘有关技术如何改变医学和生物医学研究的故事。在2011年7月加入《麻省理工学院技术评论》之前，Regalado 曾在巴西圣保罗为《科学》杂志和其他出版物撰写了关于拉丁美洲科学、技术和政治的文章。从2000年到2009年，他担任《华尔街日报》的科学记者，后任驻外特派员。



## Peter Fong


Senior Principal, Flagship Pioneering

Flagship Pioneering高级主管

Peter Fong joined Flagship Pioneering as senior principal in 2018. At Flagship, Peter leads a team of entrepreneurial scientists to develop the science, intellectual property, and business strategy that form the foundation of Flagship's next breakthrough startups.

Previously, Peter worked in oncology business development at Genentech. In this role, he focused on advancing Genentech's immuno-oncology partnering efforts, which included leading the company's \$310M partnership with BioNTech for their neoantigen cancer vaccine. Peter has also worked at Memorial Sloan-Kettering, where he managed their New Ventures and Business Development group. Prior to Memorial, he also co-founded Carigent Therapeutics. Peter is an inventor on multiple issued patents and authored numerous scientific journal articles.

Peter Fong于2018年加入 Flagship Pioneering 并担任高级主管。Peter引领一支创业型科学家团队，通过生命科学、知识产权和商业战略的多方探索为Flagship下一批突破性创业公司奠定基础。在加入Flagship之前，Peter曾在Genentech致力于推进Genentech的肿瘤免疫治疗合作项目，其中包括领导该公司与BioNTech 合作研发新抗原癌症疫苗，项目金额高达3.1亿美元。Peter还曾在Memorial Sloan-Kettering工作，负责管理他们的新风险投资和业务发展部门。他还是Carigent Therapeutics公司联合创始人之一。Peter是多项已授权专利的发明人，并撰写了大量科学论文。



## Xin He 何欣

Founder and Managing Partner, Hyfinity Fund

汇鼎投资创始人及管理合伙人

Dr. Xin He is the founder and managing partner of Hyfinity Fund. Prior to Hyfinity Fund, she was the senior partner in CDH Investments where she led the investments in medicine, equipment, and medical services, and had invested in and managed nearly 20 projects. Before joining CDH, she served as the partner of a consulting company and was the plenipotentiary partner of pharmaceutical investments of HSBC Private Equity. Dr. Xin He also founded a pharmaceutical company and served as CEO, which was operated across the U.S. and China. Dr. Xin He holds a Ph.D. in Immunology from Yale University, an M.S. in Chemistry from Princeton University, and a B.S. in Chemical Physics from University of Science and Technology of China. She has led the investments in many companies including New Century Healthcare, Kangning Hospital, ZH-Bio, Mabpharm, ICT, Nucien Pharmaceutical, AMOR, NO-ANTIBIOTICS, iPharmacare, Gennlife, Hmibiotech, and many other leading enterprises in the industry.

何欣博士是汇鼎投资创始人及管理合伙人。在创立汇鼎投资之前，她曾在鼎晖投资任高级合伙人，主导在医药、器械和医疗服务行业的投资，投资和管理近 20个项目。此前，她还曾在一家咨询公司任合伙人并担任汇丰银行私募股权医药投资的全权合作伙伴。何欣博士还曾创立一家跨国制药公司并任CEO。




**Alex Wu 吴越**

Partner, Green Pine Capital Partners  
松禾资本合伙人

Alex Wu is a Partner at Green Pine Capital Partners, a leading investor in technology and healthcare innovation in China and is responsible for Green Pine's US investments in the healthcare area. He co-founded Crown Bioscience and served as its President, CEO and CSO. In his 12-year tenure with the company, he helped build it into a global leading provider of preclinical R&D solutions for biotech and pharmaceutical companies. Alex joined Green Pine after Crown Bioscience's successful IPO and its subsequent acquisition by JSR for over \$400 million. Alex received B.S. in Biochemistry from Fudan University in Shanghai and Ph.D. and MBA from the University of California, Berkeley. He conducted post-doctoral research at Stanford University.

吴博士是中国科技与医疗创投头部基金松禾资本的合伙人，负责松禾资本在美国生物医疗领域的投资业务。他曾创立中美冠科生物技术有限公司并担任总裁、首席执行官及首席战略官；在其任职的十二年里，将中美冠科打造成全球领先的生物科技和制药公司临床前研发产品供应商；在中美冠科成功上市并被JSR株式会社以超过4亿美元的价格收购后，吴博士加入了松禾资本。吴博士本科毕业于上海复旦大学生物化学专业，后获得加州大学伯克利分校博士和工商管理硕士，还曾在斯坦福大学从事博士后研究。




**Michael Fenn**

Director, Healthcare & Life Science, Harvard Innovation Labs  
哈佛创新实验室健康与生命科学主任

Dr. Michael Fenn is tasked with advising and supporting all healthcare and life science ventures with a focus on supporting founders seeking to drive innovations in human health, which include students, research fellows, and alumni. Michael also serves as a liaison within the Harvard-affiliated healthcare and research communities, as well the surrounding Boston-area ecosystem. He is particularly passionate about bridging the gap between the academic research and venture worlds, having worked extensively in both. Michael has served as cofounder, advisor, and board member for over 25 startups, as well as several incubators and economic development committees. His entrepreneurial efforts have resulted in significant early-stage capital, creation of intellectual property, technology transfer, and navigation of regulatory pathways. Dr. Fenn received his Ph.D. in Biomedical Engineering, M.S. in Materials Science and Engineering, and B.S. in Chemistry/Biochemistry, all from the University of Florida.

Michael Fenn 博士负责为各类生物医疗创新企业提供咨询和支持，同时为所有哈佛相关的生物医疗创业社区以及泛波士顿地区的创业生态系统提供广泛的支持。Fenn博士热衷于弥合学术研究与风投领域之间的差距。Fenn博士曾担任超过 25 家初创公司以及多个孵化器和经济发展委员会的联合创始人、顾问和董事会成员。Fenn博士在创业领域的积累涵盖了早期融资、知识产权、技术转让和监管途径等多个方面。Fenn 博士在佛罗里达大学获得生物医学工程学博士学位、材料科学与工程学硕士学位和化学/生化学士学位。



**Luhan Yang 杨璐菡**

Founder & CEO, Qihan Bio; Co-founder & CSO, eGenesis  
启函生物创始人兼首席执行官；eGenesis联合创始人兼首席科学官

Dr. Yang leads a world class genome engineering team harnessing the latest gene-editing techniques with the capability to solve the global organ crisis by reinvigorating the field of xenotransplantation and offering the potential to expand the applicability of transplantation into other areas such as cell therapy. She previously developed the highly programmable genome-engineering tool, CRISPR/Cas9, for use in mammalian cells, and pioneered the first isogenic human stem cell lines to model human diseases at the tissue level. She was recently honored in the Bloomberg 50 (2017), named “Young Global Leader” by the World Economic Forum (2017) and was featured in “30 Under 30” in Science and Healthcare by Forbes Magazine (2014). Dr. Yang holds B.S. degrees in Biology and Psychology from Peking University and a Ph.D. in Human Biology and Translational Medicine from Harvard Medical School.

杨博士带领世界一流的基因组工程团队，利用最新的基因编辑技术，通过重新开发异种移植领域，为全球器官危机寻求解决方法，并有可能将移植的适用性扩展到细胞治疗等其他领域。她曾带领团队开发了高度可编程的基因组工程工具CRISPR / Cas9在哺乳动物细胞中的应用，并首次使用同基因人类干细胞系来进行组织水平的人类疾病模拟。她曾荣登2017年Bloomberg 50 排行榜，被世界经济论坛评为“年轻全球领袖”，并被“福布斯”杂志评为科学和医疗保健领域“30 Under 30” 青年领袖。杨博士曾在北京大学获生物学与心理学学位，在哈佛医学院获人类生物学和转化医学专业博士。



**Marilyn X. Zhou 周晓鸿**

CEO, Guangzhou Doublle Bioproduct  
广州达博生物制品有限公司首席执行官

Dr. Marilyn Zhou is the CEO of Guangzhou Doublle Bioproduct Co., Ltd., a biotech company focused on both gene therapeutic product development and manufacturing as well as cell therapeutic product development and services. Coming from an analytical background, she has had 26 years of experience in pharmaceutical industry, starting from research and development, analytical development and quality control, and then leading the CMC aspect of product development. In her recent career, she has also involved in the international business development. Dr. Zhou has so far held various leadership roles in 6 well-known pharmaceutical companies in the U.S. and helped these companies develop products which generate thousands of millions of dollars of revenue.

周晓鸿博士是广州达博生物制品有限公司首席执行官。该公司是一家专注于基因治疗产品开发和制造以及细胞治疗产品开发和服务的生物技术公司。她拥有26年的制药行业经验，领导研发，分析，质量控制，以及CMC的产品开发。在她最近，她还参与了国际业务的发展。周博士曾在美国6家知名制药公司担任过多项领导职务，并帮助这些公司开发生产数千万美元收入的产品。






## Armon Sharei

Founder & CEO, SQZ Biotech  
SQZ Biotech创始人和首席执行官

Dr. Armon Sharei, Ph.D. is the Founder of SQZ Biotechnologies Company and serves as its Chief Executive Officer since January 2015. He is Fellow of Harvard Medical School and holds a B.S. with Honors and Distinction from Stanford University and a PhD from MIT. Dr. Sharei work has been highlighted by numerous news outlets including Nature, Nature Methods, New Scientist, and the National Institute of Health. From 2008 to 2013, Armon pursued his PhD in Chemical Engineering under Klavs Jensen and Robert Langer at the MIT. His methods for disrupting cell membranes formed the foundation of SQZ Biotech in 2013. Co-founded with Jensen and Langer, the company aims to use the squeeze mechanism to power cells to fight diseases, including cancer and autoimmune diseases. The idea has been met with wide excitement. In 2014, Scientific American featured it as one of the year's Top 10 World Changing ideas. The following year, Fierce Biotech ranked SQZ amongst fifteen world-changing biotech companies.

Armon Sharei 博士是SQZ Biotech 创始人和首席执行官。他获斯坦福大学学士学位，麻省理工学院化学工程博士学位，并在哈佛医学院完成博士后。他研发的破坏细胞膜的新方法为SQZ Biotech 公司提供了科研基础。SQZ Biotech 公司旨在利用挤压机制驱动细胞来对抗包括癌症和自身免疫性疾病在内的疾病。2014年，“Scientific American”将其作为今年十大改变世界的创新想法。Armon Sharei博士创立的SQZ公司曾被评为十五家改变世界的生物技术公司。




## Lan Cao

Senior Director, Head of Product Development & Global Program Leader, Cell Therapy,  
Takeda 武田药品细胞治疗资深主管

Lan Cao is currently the Senior Director, Head of Product Development in the Translational Engine, Cell Therapy group at Takeda, focusing on product development for various cell therapy products, including CAR-T, iPSC-derived T cells, gamma-delta T cells, and CRSIPR gene editing. Lan has more than 10 years' experience in the cell therapy field in pharmaceutical and biotech companies (CRISPR Therapeutics, Unum Therapeutics, Battersea Biotech and Novartis) with increasing roles and responsibilities, including leading the process development of the first FDA approved CAR-T product, Kymriah. Lan has been the key CMC leader in filing multiple INDs and BLAs for cell therapy products. Lan received his Ph.D. in Chemical Engineering from the University of Washington, and postdoctoral training at Harvard University, Bioengineering.

Lan Cao 博士现任武田药品细胞治疗资深主管，产品研发与全球化负责人，负责各种细胞治疗产品的开发，包括CAR-T，iPSC衍生T细胞， $\gamma$ - $\delta$ T细胞，和CRSIPR基因编辑。曹博士在生物技术制药公司的细胞治疗领域拥有超过10年的经验。曹博士带领团队完成了多项细胞治疗产品的化学与生产控制(CMC)的研究性新药申请(IND)和生物制剂许可证申请(BLA)。在加入武田之前，曹博士先后在Novartis, Unum Therapeutics, Battersea Biotec 和CRISPR Therapeutic 负责领导细胞治疗方向的产品研发，其中包括FDA批准的第一个CAR-T产品Kymriah。曹博士于华盛顿大学化学工程专业获得博士学位，并在哈佛大学完成生物工程博士后。



## Sally Wang Liang 梁王渊恒

Biopharma & Health Tech Executive and Lawyer; General Counsel, U.S.-China Health  
Summit 生物制药与健康科技企业家和律师

Sally Wang Liang is a biopharma & health tech business executive as well as a multidisciplinary IP & Regulatory lawyer. She worked in digital health as the CEO and Co-founder of an international telemedicine company that bridges US-China healthcare and as Chief Strategy Officer and EVP of IP and Regulatory of a leading digital therapeutics company. She practiced patent litigation and IP licensing in a premier intellectual property firm, Venable-Fitzpatrick, and clerked for a federal judge at the prestigious Southern District of New York. She advised many of the world's largest pharmaceutical companies and top biotech firms on business strategy as a management consultant; her clients include Pfizer, Sanofi, Novartis, Roche-Genetech, etc. She was a legal-policy fellow at the Food and Drug Administration and the US Senate Health Education Labor Pension Committee Health Office. She also serves as General Counsel of the US-China Health Summit. Sally received a B.A. in Biology from Harvard College, a J.D. from Harvard Law School, and a M.P.H from Harvard T.H. Chan School of Public Health.

梁王渊恒博士是一位生物制药与健康科技企业家和一名多学科背景的知识产权与监管律师。在数字医疗领域，她担任过一家连接美中医疗的国际远程医疗公司的首席执行官和联合创始人，也曾在一家顶尖数字治疗药物公司担任首席战略官和知识产权与监管高级副总裁。梁王博士曾在Venable-Fitzpatrick 从事专利诉讼和知识产权许可业务，并担任过纽约南区联邦大法官高级助理。她曾为多家国际大型药企和生物科技公司提供商务咨询，其中包括Pfizer, Sanofi, Novartis, Roche-Genetech等。梁王博士也曾就任美国食品和药物管理局FDA和美国参议院健康教育劳工养老金委员会卫生健康办公室的法律政策研究员。她目前是中美健康峰会的法律总顾问。梁王博士毕业于哈佛大学生物本科，哈佛法学院法学博士和哈佛大学T.H. Chan公共卫生学院公共卫生硕士。




## Jeffrey J. Ellison

Partner, Clark+Elbing  
Clark+Elbing合伙人

Jeffrey Ellison advises clients on a wide range of patent-related matters, including the preparation and prosecution of patent applications; management of complex patent portfolios; analysis of patent validity, enforceability, and infringement issues; and drafting of patent licenses and other agreements concerning the development and/or transfer of technology. He is well-versed in patent portfolio management and the interplay of intellectual property with FDA regulatory matters. His practice emphasizes inventions in various areas of technology, including general chemistry, polymers, pharmaceuticals, diagnostic agents, diagnostic methods, cosmetics, drug delivery systems, nutraceuticals, and medical devices.

Jeffrey Ellison 博士在专利相关的各类事务上为客户提供咨询，包括专利申请的准备和起诉；管理复杂的专利组合；专利有效性、可执行性与侵权问题分析；以及起草专利许可证和其他有关技术开发和（或）转让的协议。他精通专利组合管理以及美国食品药品监督管理局（FDA）对知识产权的监管条例。他的业务专注于各个领域的技术发明，包括普通化学、聚合物、药物、诊断试剂、诊断方法、化妆品、给药系统、保健营养品和医疗器械。




## Can Cui 崔燦

Associate, Morrison Foerster  
美富律师事务所律师

Dr. Can Cui is an associate in the San Francisco office of Morrison & Foerster. As a member of the Firm's Technology Transactions Group, his practice focuses on China-related Life Sciences transactions, including cross-border technology licensing and acquisitions, collaboration and strategic partnerships, and joint ventures and other forms of investments. In PE/VC investments, he has represented both institutional and individual investors and start-up and established Life Sciences companies in Intellectual Property and technology due diligence and negotiating and drafting investment documentation. Dr. Cui also advises clients on the IP aspects of mergers and acquisitions. Dr. Cui received his J.D., magna cum laude, from New York University School of Law, where he was the Senior Articles Editor and Board Member of NYU Journal of Law & Business.

崔燦博士是美富律师事务所旧金山办事处律师。作为该事务所技术交易组成员，其业务专注于与中国相关的生命科学交易，包括跨境技术许可与收购、合作与战略伙伴协议、合资以及其他形式的投资项目。崔博士在美国国内及跨太平洋地区的生命科学许可交易中代理许可方和被许可方，有着丰富的经验。在私募投资和风险投资项目中，他代理机构和个人投资者、初创及知名生命科学公司处理知识产权事务和进行技术尽职调查、谈判及撰写投资文件。崔博士还在并购中为客户提供知识产权方面的咨询。崔博士以最优等毕业生的荣誉获得纽约大学法学院法学博士学位。就读期间，他曾担任《纽约大学法律与商业学报》的资深论文编辑及编委会委员。



## Jonathan Darrow

Assistant Professor, Program on Regulation, Therapeutics & Law, Harvard Medical School  
哈佛医学院政策、治疗与法律中心助理教授

Jonathan J. Darrow joined the faculty of Harvard Medical School and the Program on Regulation, Therapeutics, and Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in 2016, following service as Senior Law Clerk to a judge on the United States Court of Appeals for the Federal Circuit, the court that decides all patent appeals involving pharmaceuticals, biologics, and medical devices. He holds degrees in biological sciences / genetics, law, and business from Cornell, Duke, and Boston College, respectively, as well as a research doctorate in pharmaceutical policy and intellectual property theory from Harvard, where he also completed the LL.M. program.

Jonathan J. Darrow教授于2016年加入哈佛大学医学院以及布莱根妇女医院药物流行病学和药物经济学分部的管理、治疗与法律系，此前曾在美国联邦巡回上诉法院从高级法律助理做到法官，该法院负责审判所有涉及医药、生物制品、医疗器械的专利上诉案件。他持有康奈尔大学生物科学/遗传学学位、杜克大学法律学位和波士顿学院商业学位，还在哈佛大学获得了药物政策和知识产权理论研究博士学位并完成了法学硕士课程。



## Rushika Fernandopulle

Co-founder and CEO, Iora Health  
Iora Health创始人兼首席执行官

Rushika Fernandopulle is a practicing physician and co-founder and CEO of Iora Health, a venture backed, national de-novo primary care group based in Boston MA. He was the first Executive Director of the Harvard Interfaculty Program for Health Systems Improvement, and Managing Director of the Clinical Initiatives Center at the Advisory Board Company. He is a member of the Albert Schweitzer, Ashoka, Aspen, and Salzburg Global Fellowships, and is co-author or editor of several publications including Health Care Policy, a textbook for physicians and medical students, and Uninsured in America: Life and Death in the Land of Opportunity. He serves on the staff at the Massachusetts General Hospital (MGH), on the faculty of Harvard Medical School, and on the boards of Families USA and the Schwartz Center for Compassionate Care. He earned his A.B., M.D., and M.P.P. (Masters in Public Policy) from Harvard University, and completed his clinical training at the University of Pennsylvania and the MGH.

Rushika Fernandopulle 是 Iora Health 的执业医师和联合创始人兼首席执行官。Iora Health位于麻省波士顿，是一家由风投资助的全国首家创新基础医疗组织。Rushika是哈佛大学卫生系统改进计划的第一任执行主任，以及咨询委员会公司临床计划中心的常务董事。他是 Albert Schweitzer, Ashoka, Aspen和Salzburg Global Fellowships的成员，并出版或编辑包括《医疗保健政策》以及《美国的无保险：机遇之地的生与死》。他是麻省总医院和哈佛医学院的教职员工，也是美国家庭和Schwartz慈善医疗中心的董事会任职。他在哈佛大学获得了文学学士学位，医学博士学位和公共政策硕士学位，并在宾夕法尼亚大学和麻省总医院完成临床培训。



## Michael Greeley

Co-founder and General Partner, Flare Capital  
Flare风险投资创始合伙人

Michael was the founding General Partner of Flybridge Capital Partners where he led the firm's healthcare investments. Prior to Flybridge, Michael was a senior vice president and founding partner of GCC Investments, and held positions at Wasserstein Perella & Co., Morgan Stanley & Co., and Credit Suisse First Boston. Michael serves on the Industry Advisory Board of the Cleveland Clinic and Boston Children's Hospital, as well as serving on several other boards including the Governor's Digital Health Council and the Massachusetts Technology Collaborative. Michael also serves on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye & Ear Infirmary. He was the former chairman of the New England Venture Capital Association. Named by the Boston Globe as the "Go-To" investor for life sciences, healthcare and medical devices and a Mass High Tech All-Star, Michael earned an M.B.A. from Harvard Business School.

Michael曾是Flybridge资本合伙公司的创始合伙人，负责领导该公司的医疗保健类投资项目。在加入Flybridge之前，Michael曾是GCC投资公司的高级副总裁和创始合伙人，并曾在Wasserstein Perella&Co.、摩根士丹利和瑞士信贷第一波士顿银行任职。现在，他在克利夫兰诊所和波士顿儿童医院的行业顾问委员会任职，也是马萨诸塞州眼科及耳科医院的投资委员会成员。他曾是新英格兰风险投资协会的主席，也是国家风险投资协会董事会的执行委员会的一员。他曾被《波士顿环球报》评为生命科学、医疗保健和医疗设备领域里的最权威投资者，他是大规模的高科技领域的明星投资人。他于哈佛商学院取得了工商管理硕士学位。



**Beth Bierbower**

Segment President, Humana  
Humana 保险副总裁

Beth Bierbower is Segment President for Humana. She is responsible for creating a new operating model and member experience that reduces friction in the system and helps members engage in and manage their health. In her prior role, Beth led Humana’s Group and Specialty Business segment, with responsibility for Humana’s Employer Group products including medical, specialty and individual specialty offerings, and Humana’s Government Business. Beth started her career at Humana in 2001. As Product Innovation Leader, she drove the consumer strategy that included development of new products and services that helped position Humana as a leader in consumerism. Beth has published a book titled Engage! A Guide to Involving Your Consumers in their Health. She earned a master’s in public management, graduating with highest honors, from Carnegie Mellon University.

Beth Bierbower 是Humana保险的副总裁。她负责创建新的运营模式和会员体验，以减少系统中的摩擦，并帮助会员参与和管理他们的健康。在此之前，Beth领导Humana集团和专业业务部门，负责Humana的雇主集团产品，包括医疗、专业和个人专业产品，以及Humana的政府业务。Beth于2001年在Humana开始了她的职业生涯。作为产品创新领导者，她推动消费者战略，包括开发新产品和服务，帮助Humana成为消费主义的领导者。Beth出版过书籍《参与！让消费者参与其健康的指南》。她获得了卡内基梅隆大学的公共管理硕士学位并以最高荣誉毕业。



**Stephen Knight**

President and Managing Partner, F-Prime Capital  
F–Prime Capital主席与管理合伙人

Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Steve serves on the Board of Directors of Beam Therapeutics, Geneception, Genomics plc, Innovent Biologics, Iora Health, Pulmocide, Sana Biotechnology and Semma Therapeutics. Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.

Stephen Knight 于2003年加入F–Prime投资基金，担任总裁和执行事务合伙人。他在制药和生物科技行业工作超过25年，在医疗保健领域也有着丰富的投资经验，还是BeamTherapeutics、Geneception、Genomics plc、信达生物制药、IoraHealth、Pulmocide、Sana Biotechnology和Semma Therapeutics的董事会成员。在加入F–Prime投资基金前，他曾在私营和上市生物科技及咨询公司担任高管，也曾任AT&T贝尔实验室、美国国立卫生研究院和耶鲁大学从事研究工作。他持有耶鲁大学医学院医学博士学位、耶鲁大学组织与管理学院工商管理硕士学位，并在哥伦比亚大学获得生物学学士学位，以最优等毕业生和全美大学优等生之荣誉毕业。



**Kevin Xie 谢懿立**

President, Fosun Healthcare Holdings; U.S. Executive Chief Representative, Fosun Group  
复星健康控股总裁，纽约办公室执行首席代表

Kevin Xie is the President of Fosun Healthcare Holdings and Chief Representative of Fosun U.S. office. In his current role, Mr. Xie is responsible for Fosun Group's global healthcare investments in both primary and public market. Prior to joining Fosun in 2015, Mr. Xie co-founded Locust Walk Capital, a global healthcare hedge fund. Before that, He served as the healthcare sector head at Scopia Capital, a multi-billion USD market neutral long-short equity hedge fund. He was a portfolio manager and managing director at Great Point Partners, a premier healthcare hedge fund / private equity fund. Mr. Xie holds an MBA from The Wharton School, a PhD in Chemistry from City University of New York, and a BS in Material Engineering from Tianjin University.

谢懿立先生目前担任复星健康控股总裁，纽约办公室执行首席代表。他负责全面领导团队进行大健康资产的配置与投资，拥有超过15年的该领域投资经验。在加入复星集团之前，谢先生共同创建大健康对冲基金Locust Walk Capital。在此之前，他曾担任Scopia资本的医疗投资负责人，该对冲基金管理资产逾数十亿美元；他曾任私募股权基金Great Point Partner的董事总经理，管理其医疗领域的对冲基金与私募股权基金。谢先生拥有宾夕法尼亚大学沃顿商学院MBA及纽约城市大学化学博士学位，天津大学材料工程本科学位。



**Tiger Tang 汤敏超**

Co-founder, CEO, iBridge TT International LTD; Chairman & CEO, Tangbridge Think Tank  
易创科技国际有限公司的联合创始人兼首席执行官；易可道智库董事长兼首席执行官

Tiger is the co-founder & CEO of iBridge International TT, a private accelerator and Tang Bridge, a think tank, both based in Guangzhou. Tiger has extensive experience running businesses and providing services for governmental departments, publicly listed companies, MNCs, SOEs, SMEs, NGOs and think tanks. Among his many former roles, he was the founder and former president of Guangzhou International Biotech Island and the founder of the Foreign Investment Promotion Office, Guangzhou Development District. Tiger is an expert in theory and practice of new-models of urbanization and industrial-urban integration, especially in the overall strategic planning, operation, investment promotion and talent attraction for development zones (high-tech zones, bio-industrial and other emerging industrial parks).

汤敏超先生是易创科技国际有限公司（iBridge TT International Ltd.）的联合创始人兼首席执行官。易创科技国际有限公司是聚焦全球先进生物技术和健康技术加速器和产业园专业运营商。汤先生在为政府部门、跨国公司、上市公司、、国有企业、中小企业、非政府组织和行业商协会提供专业化和国际化服务方面拥有丰富的经验。他是广州国际生物科技岛的创始人和首任总裁，也是广州开发区外商投资促进中心（局）首任负责人，广州跨国公司联谊会创始人。汤先生是产城融合、产城运营新模式、生物产业开放创新生态系统的理论和实践专家，特别是在开发区（高新区，生物产业园）的整体战略规划、投资促进、人才引进和产业运营管理方面有丰富经验和诸多成功案例。






**Corey McCann**

President and CEO of Pear Therapeutics  
Pear Therapeutics创始人兼首席执行官

Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey's central nervous system expertise group, advising clients across the healthcare value chain. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early stage investments, and at NeuroInsights, where he evaluated brain-related technologies. Corey is also a co-founder, advisor, or Board Director at AgNovos Healthcare, Alcyone Lifesciences, Dragonfly Sciences, Edumedics, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health.

此前，Corey是MPM Capital的一名投资人，负责评估医疗保健领域里新的投资机会，管理战略合作伙伴关系，并监督投资组合公司的战略与执行。在加入MPM之前，他在麦肯锡公司担任业务经理，负责为制药、医疗器械和生物技术公司提供生命科学技术收购、开发和商业化等方面的咨询。他曾领导麦肯锡中枢神经系统专家组，为整条医疗价值链上各个环节的客户提供咨询服务。Corey曾在RiverVest风险投资合作公司负责对早期投资进行尽职调查，在NeuroInsights公司负责对大脑相关技术进行评估。Corey还是Agnovos 医疗保健公司、Alcyone生命科学公司、Dragonfly科技公司、Edumedics、Resolute Bio、Selexys Pharmaceuticals和Zillion Health的联合创始人、顾问或董事会董事。



**David Mou**

Co-founder and Chief Medical Office, Valera Health; Psychiatrist at Massachusetts General Hospital  
Valera Health 联合创始人及首席医疗官；麻省总医院精神科医生

David is the co-founder and Chief Medical Officer of Valera Health, a venture-backed digital healthcare company that empowers healthcare organizations to better manage chronic medical and mental health conditions. David is also a psychiatrist at Massachusetts General Hospital, where he conducts research on how digital data could help clinicians predict suicidal thoughts and behaviors. He is a Soros Fellow, a Horatio Alger National Scholar, and a Blavatnik Fellow in Life Science Entrepreneurship at Harvard Business School. He graduated from Harvard College with an honors degree in neurobiology, and earned his MD MBA from Harvard Medical School and Harvard Business School. His writings have appeared in the New England Journal of Medicine.

David是Valera Health的联合创始人以及医疗总监。Valera Health是一家风投提供资金支持的数字医疗公司，旨在提高医疗组织管理慢性病以及精神健康状况。David是马萨诸塞州总医院的精神病医生，研究电子数据如何帮助临床医生预测自杀想法和行为。在哈佛商学院期间，他曾获得索罗斯学者（Soros Fellow），霍雷肖·阿尔杰国家学者（Horatio Alger National Scholar）和生命科学企业家布拉瓦尼克学者（Blavatnik Fellow）的称号。David毕业于哈佛大学并获得神经生物学荣誉学士学位，于哈佛医学院获得医学博士学位，并于哈佛商学院获得工商管理硕士学位。他也为《新英格兰医学》杂志撰稿。



**Joseph Kvedar**

Vice president, Connected Health, Partners Healthcare  
Connected Health, Partners Healthcare副总裁

Dr. Joseph Kvedar is creating a new model of health care delivery, moving care from the hospital or doctor's office into the day-to-day lives of patients. At Partners HealthCare, Dr. Kvedar is leveraging personal health technologies to improve care delivery and help providers and patients better manage chronic conditions, maintain health and wellness and improve adherence, engagement and clinical outcomes. He has launched a number of innovative health tracking programs, mobile health, virtual care initiatives and clinical research programs for the more than 1.5 million patients served at Partners HealthCare-affiliated hospitals. Dr. Kvedar serves as Program Chair for the Connected Health Conference, an industry defining event co-hosted by Partners Connected Health and the HIMSS Personal Connected Health Alliance (PCHAlliance). He is also a member of the PCHAlliance Board of Managers.

在Partners Healthcare，Joseph Kvedar 博士利用个人健康技术改进医疗递送，帮助医疗人员和患者更好地管理慢性疾病，保持身心健康，提高依从性、参与度和临床结局。他为Partners HealthCare的附属医院的150多万名患者推出了包括医疗跟踪项目、移动医疗、虚拟医疗计划和临床研究等一系列创新项目，Kvedar博士还是互联健康大会（Connected Health Conference）的项目主席，这是一个由Partners Connected Health和医疗卫生信息与管理系统协会（HIMSS）个人互联健康联盟（PCHAlliance）共同主办的行业活动。Kvedar博士也是PCHAlliance管理委员会的成员。



**Ligang Zhang 张黎刚**

Founder, Chairman & CEO, iKang Health  
爱康国宾创始人、董事长兼首席执行官

Mr. Ligang Zhang has been a successful serial entrepreneur and business executive. Mr. Zhang founded iKang Healthcare Group, Inc. ("iKang") in 2004, and has been serving as iKang's Chairman and Chief Executive Officer. iKang was listed on the NASDAQ in April 2014 and privatized in January 2019. Prior to iKang, Mr. Zhang was a co-founder of eLong.com and served as CEO from 1999 to 2003. From 1998 to 1999, Mr. Zhang served as head of product development at Sohu.com, a leading NASDAQ-listed Chinese Internet portal. Mr. Zhang founded the journal Harvard China Review in 1997 and co-founded the Harvard China Forum in 1998 while studying at Harvard University.

张黎刚先生是一位在医疗服务与互联网领域的成功创业者，张黎刚先生在2004年创立了爱康网，并一直担任爱康集团董事长与首席执行官。爱康集团是中国中高端私营预防医疗服务领域的领导者，于2014 年在美国纳斯达克成功上市，2019年完成私有化。在此之前，张黎刚先生联合创立了艺龙网，并从1999年到2003 年担任首席执行官。从1998年到1999年，张黎刚前后担任了搜狐网产品经理和产品总监。搜狐网和艺龙网前后于纳斯达克成功上市。在哈佛大学就读研究生期间，张黎刚先生创立了《哈佛中国评论》期刊和哈佛中国论坛。



## Lingyun Su 苏凌云

Lingyun Su, was the inaugural director of Alibaba Health Research Center. His works span across fields from data science, industry and policy trends, strategy and investment, to data security and privacy protection on the Chinese healthcare sectors covering medical, pharmaceutical, insurance, and wellness areas. Lingyun had led many consulting and research data modeling projects at IMS Health and Eli Lilly in US. His works then had covered many areas of the pharmaceutical commercial operations ranging from sales operations, marketing effectiveness, payer pricing and reimbursement, healthcare affordability, integrated delivery networks, etc. At IMS Health, he was instrumental in providing analytical leadership for several major multi-national post merger sales force redesigns and optimizations. At Eli Lilly, he provided the critical decision support analytics for the successful launch of Byetta as well as for the establishment of Lilly's hospital business unit. Lingyun worked at IRI providing clients in the consumer packaged goods industry with data driven decision support.

苏凌云是前阿里健康研究中心资深总监。他在阿里致力于推动中国大健康产业的多学科交叉研究包括医疗、医药、保险和健康相关领域的研究。他曾在IMS Health和美国Eli Lilly（礼来）领导众多咨询和研究性数据模型项目。他的工作涵盖医药企业商业运营中的销售运营、营销效益、支付方定价、报销、可支付性分析、医联体影响等诸多环节。在IMS Health，他担任统计部先进分析总监曾主持多起重大的跨国并购后销售的重新设计和优化。在Eli Lilly，他的量化分析对抗糖尿病药物百泌达（Byetta）的成功上市以及Lilly医院业务单元的成立起到了决策支持作用。在此之前，苏凌云就职于IRI，为美国快销零售业客户公司提供领先的定量决策分析。苏凌云毕业于北京大学数学系和芝加哥大学统计学系。



## Rick Williams

Former President, Boston Harvard Business School Alumni Association;  
Managing Director, William Advisory Partners  
哈佛商学院校友会（波士顿地区）前主席；William Advisory Partners创始人兼总经理

Rick Williams is Managing Director of Williams Advisory Partners, LLC. He has a breadth of experience as an executive and board director for technology companies including medical technology, software, and financial services. He was Chairman of the Board of Point Care Technologies and formerly was Chairman of a quasi-public bank/VC firm. Rick is on the board of Amorphex Therapeutics an ocular drug delivery company and MedTherapy Technology a leader in gene therapy. Rick is past President of the Harvard Business School Association of Boston. He was a management consultant with the global consulting firm Arthur D. Little, Inc., working on business strategy and acquisitions and the economic and strategic impact of government policy and regulations on a broad spectrum of industries.

Rick Williams是Williams Advisory Partners咨询公司的董事总经理。他曾在Point Care 技术公司担任过董事会主席，此前他还是一家准公共银行/风险投资公司担任主席。Rick现在是眼科药物输送公司Amorphex Therapeutics和基因治疗公司MedTherapy的董事会成员。Rick还是哈佛商学院协会的波士顿区前任主席，曾在全球咨询公司Arthur D.Little从事管理咨询，涵盖不同行业，从事商业战略和收购、政府政策和法规在经济上和战略上的影响等方向的咨询。




## Debra Bass

Global CMO & U.S. President, Nuvo Cares  
Nuvo Cares全球首席营销官和美国区总裁

Nuvo has a bold ambition to reinvent pregnancy management for the 21st century with new technology, tools, and practices to give every life a better beginning. Debra is currently Global CMO and President of the United States at Nuvo Group, an emerging leader in maternal fetal connected health. In this capacity, she is building the Nuvo global brand platform and assets and is preparing the U.S. for a lead market launch. Before joining the Nuvo Group, Debra was President, Global Marketing Services at Johnson & Johnson (J&J) Consumer Companies. She was responsible for leading a team of 200+ and accelerating profitable growth behind J&J's \$14B portfolio of global and regional brands. Prior to this role, Debra was Global President of the \$2B+ Global Baby Care Franchise. Debra is active industry speaker and has spoken at Cannes Lion's Health, Modern Marketing Summit, and New York Advertising Week. She was recently recognized as one of the "Top 100 Women in FemTech" and as the "Most Powerful and Influential Women".

Debra Bass 女士目前是Nuvo集团的全球首席营销官和美国区总裁，该集团是孕产妇胎儿健康的新兴领导者。她正在构建Nuvo全球品牌平台和资产，并正在登陆美国市场。在加入Nuvo集团之前，Debra是强生集团（J&J）消费者公司的全球营销服务总裁。她领导一支200多人的团队，并负责推动强生公司140亿美元品牌组合的全球盈利增长。在此之前，Debra是一家20亿美元的婴儿保健连锁公司的全球总裁。Debra是活跃的行业演讲者，曾在多个顶级健康和市场营销会议上发表演讲。她最近被评为“女性科技领域百强女性”和“最具实力和影响力的女性”之一。



## Yasheng Huang

Associate Dean and Professor, MIT Sloan School of Management  
MIT Sloan商学院副院长、教授

Yasheng Huang is the International Program Professor in Chinese Economy and Business and a Professor of Global Economics and Management at the MIT Sloan School of Management. He is also an Associate Dean at MIT Sloan School of Management. Huang founded and runs the China Lab and the India Lab, which aim to help entrepreneurs in those countries improve their management skills. He is an expert source on international business, political economy, and international management. In collaboration with other scholars, Huang is conducting research on human capital formation in China and India, entrepreneurship, and ethnic and labor-intensive foreign direct investment (FDI). Prior to MIT Sloan, he held faculty positions at the University of Michigan and at Harvard Business School. Huang also served as a consultant to the World Bank.

黄亚生教授是美国麻省理工（MIT）斯隆管理学院政治经济和国际管理教授,同时担任斯隆管理学院的副院长。在斯隆管理学院,黄教授创办了“中国实验室”和“印度实验室”，目的是帮助中印两国企业提高管理能力。黄教授的主要研究领域涉及国际商务管理、政治经济学和跨国企业管理。在进入斯隆管理学院之前，黄教授也曾在密歇根大学和哈佛商学院担任教职，并同时在世界银行兼任顾问。除此之外，黄教授还兼任清华大学中国经济研究中心研究员，北京大学国际关系学院研究员，密歇根商学院威廉大卫逊学院研究员，世界经济论坛研究员。



## Richard Gliklich

Founder & CEO, OM1  
OM1创始人、首席执行官

Dr. Richard Gliklich is CEO of OM1, a health outcomes and technology company leveraging big clinical data and AI to better understand, compare, and predict patient outcomes. Previously, Dr. Gliklich founded and led Outcome, a registries and comparative effectiveness company, as the CEO through its acquisition. After that, Dr. Gliklich was an XIR at General Catalyst Partners focused on investments in healthcare companies, until founding OM1 in 2015.

Dr. Gliklich is PI and senior editor of the Agency for Healthcare Research and Quality (AHRQ)'s Registries for Evaluating Patient Outcomes: A User's Guide 1st - 4th editions, the worldwide reference document for understanding quality in real world studies and registries. He leads the Outcome Measures Framework, a U.S. government-funded effort to standardize health outcomes measurement across and within conditions.

Richard Gliklich博士是OM1的创始人和CEO。OM1利用海量临床数据和人工智能帮助人们理解、比较和预测治疗结果。此前，Gliklich博士作创立了Outcome，另一家专注医疗结果比较的公司，并一直作为CEO直到被收购。在那之后，Gliklich博士作为顶级风投机构General Catalyst 专注大健康领域的入驻高管，直到2015年成立OM1。Gliklich博士是美国医疗保健研究和质量中心（AHRQ）评估患者结果的注册管理机构的高级编辑和研究员，这是用于评估现实世界研究和注册管理机构质量的全球参考文件。他领导完成了“Outcome Measures Framework”，一项由美国政府资助并旨在规范健康结果的测量的研究。




## Kuldeep Singh Rajput

Founder & CEO, Biofourmis  
Biofourmis创始人、首席执行官

Recognized as the “Forbes 30 Under 30”, Kuldeep has demonstrated strong leadership experience with building teams, developing talents, and successfully growing, and managing strategic partnerships with global pharmaceutical manufacturers, health systems and Payers. Under his leadership, Biofourmis has raised over US\$45 Million in venture capital from leading Venture Capital firms including Sequoia Capital, MassMutual Ventures, Singapore Govt-linked EDBI, Aviva plc, and Mayo Clinic Ventures. He uses his background and experience in biomedical engineering and data from the Massachusetts Institute of Technology (MIT) to unfold his vision of “Predicting and Preventing Serious Medical Events using AI”. During his Ph.D. studies at the National University of Singapore (NUS), he built bioelectronic implants, which aim to control biological processes and treat diseases by modulating electric impulses.

2019年，在健康和科技领域，Kuldeep被评为“福布斯30位最杰出30岁以下人士”。他在建立团队、培养人才、企业增长以及管理战略合作等方面展现出强大的领导力。在他的领导下，Biofourmis已经从顶级风投公司筹集了超过4500万美元的投资，其中包括Sequoia Capital, MassMutual Ventures, 新加坡EDBI, Aviva plc 和 Mayo Clinic Ventures。Kuldeep利用自己在麻省理工学院（MIT）的生物医学工程和数据方面的背景和经验，推动其“使用人工智能预测和预防严重医疗事件”的愿景。在他的博士期间，他在新加坡国立大学（NUS）研究生物电子植入物，旨在通过调节电脉冲来控制生物过程和治疗疾病。



## Matt Deng 邓昱枫

CEO, Infervision North America  
推想科技北美首席执行官

Dr. Matt Deng is the CEO of Infervision North America, who leads the Business development and R&D efforts of Infervision in the U.S. He holds a Ph.D. degree in Biomedical Engineering from Duke University. He has authored over 20 publications in deep learning and medical imaging, and a former system engineer at Siemens Healthcare.

邓昱枫博士是推想科技北美区的CEO，负责推想科技在美国的业务发展和研发工作。他拥有杜克大学生物医学工程的PhD学位，曾发表20多篇深度学习和医学影像方面的论文。加入推想科技之前，邓博士曾是西门子医疗集团的系统工程师。



## Stephen Kennedy Smith

Principal and Board Member of Park Agency Enterprises, Kennedy Family Office  
肯尼迪家族公司Park Agency Enterprises主管与董事会成员

Stephen Kennedy Smith is a principal at Park Agency - Joseph P. Kennedy Enterprises, the Kennedy family office, and an investor and entrepreneur. Stephen also is the editor of JFK- a Vision for America, published by Harper Collins. Stephen is currently a lecturer at the Sloan school of Management in the visionary investing program, as well as a fellow at the Connection Science Group at MIT. He currently involved as a board member, advisory board member or partner in a number of health care and technology businesses. His current investment and business focus is scaling innovative healthcare, and neuroscience companies.

斯蒂芬·肯尼迪·史密斯是约瑟夫·肯尼迪企业（Joseph P. Kennedy Enterprises），肯尼迪家族理财办公室Park Agency的主要负责人之一，同时还是一位投资者和企业家。斯蒂芬也是由哈珀·柯林斯出版集团出版的《肯尼迪—美国愿景》一书的编辑。现在斯蒂芬在斯隆管理学院担任长远投资这一课程项目的讲师，同时也是麻省理工学院Connection Science杂志的成员。目前，他还以董事会成员、顾问委员会成员以及合伙人的身份，加入了多个医疗保健公司和技术公司。他目前的投资和业务重点是扩大创新医疗公司和神经科学公司的规模。



## Clement Dai 戴华

Special Assistant to Stephen Kennedy Smith  
Stephen Kennedy Smith 特别助理

Clement Dai is Special Assistant to Stephen Kennedy Smith. In this role, he assists Mr Kennedy Smith at a number of organizations including New Frontier Bio, a healthcare and biotech investment holding company, John F. Kennedy Library Foundation, Kennedy Family Office and so forth.

戴华是斯蒂芬肯尼迪史密斯(Stephen Kennedy Smith)的特别助理。他协助肯尼迪史密斯先生在多家组织中的工作，包括医疗和生物技术投资控股公司New Frontier Bio、肯尼迪总统图书馆基金会、约翰·肯尼迪家族办公室等



# Speakers & Moderators 嘉宾简介 – DAY TWO



## Yuanli Liu 刘远立

Dean, School of Public Health, CAMS & Peking Union Medical College (PUMC)  
中国医学科学院–北京协和医学院公共卫生学院院长

Dr. Yuanli Liu, has been serving as Professor of Health Policy and Management and Dean of School of Public Health at the Chinese Academy of Medical Sciences & Peking Union Medical College since 2013. Before 2013, Dr. Liu worked at Harvard School of Public Health in the area of global health policy and practice. During this time, he served as one of the founding faculty members of a new doctoral major in health systems and served as the founding director of Harvard China Health Initiative. Since returning to his home country in 2013, Dr. Liu had been closely involved in China's healthcare reform and development initiatives as one of the leading policy advisers and organizers of top Think-Tank and social organizations. In 2017, Dr. Liu was named one of the top 50 most influential people in China with an overseas education and working background.

刘远立教授自2013年起担任中国医学科学院和北京协和医学院卫生政策与管理教授与中国医学科学院–北京协和医学院公共卫生学院院长。2013年之前，刘远立教授一直在哈佛大学从事国际卫生政策与实施的科研和教学工作。期间他作为联合创始人创立了“卫生体系学”，被任命为哈佛大学公共卫生学院“中国行动计划”主任。2013年回国后，即作为顶级智库和社会组织的主要政策顾问和组织成员密切参与中国的医疗改革和发展计划。2017年，刘远立教授被评为中国具有海外教育及工作背景的最具影响力的50人之一。



## Lincoln Chen

President, China Medical Board  
美国中华医学基金会主席

Lincoln Chen was the Taro Takemi Professor of International Health at the Harvard-Chan School of Public Health, Director of the University-wide Harvard Center for Population and Development Studies, and the founding Director of the Harvard Global Equity Initiative. Dr. Chen served as Executive Vice-President of the Rockefeller Foundation and Representative of the Ford Foundation in India and Bangladesh. He also served as Special Envoy of the WHO Director-General on Human Resources for Health, founding board chair of the Global Health Workforce Alliance, and founding member of the Advisory Board to the UN Secretary-General of the United Nations Fund for International Partnership. Dr. Chen also serves as a Board Member of BRAC USA, the Institute of Health Metrics and Evaluation (University of Washington), the Carso Instituto de la Salud, and the Public Health Foundation of India. .

陈致和曾担任哈佛大学陈曾熙公共卫生学院Taro Takemi 国际卫生教授、哈佛大学人口与发展研究中心主任，以及哈佛大学全球平等项目创始主任。陈博士曾在洛克菲洛基金会任执行副主席、在福特基金会任驻印度和孟加拉国首席代表。他还曾是世界卫生组织总干事在卫生人力资源方面的特别大使，全球卫生人力资源联盟创始主任，以及联合国国际伙伴关系基金联合国秘书长顾问团的创始成员。陈博士目前是BRAC USA 理事会主席，美国华盛顿大学卫生计量与评估研究所、Carso健康研究中心、印度公共卫生基金会的理事。



## Qizhu Tang 唐其柱

Vice President, Wuhan University 武汉大学副校长  
President, Hubei Provincial People's Hospital 湖北省人民医院院长

Prof. Tang Qizhu, vice president of Wuhan University, dean of School of Medicine of Wuhan University, president of Hubei Provincial People's Hospital, is also a professor, chief physician and doctoral supervisor of cardiovascular medicine. He was also the winner of the 11th Chinese Physician Award. Prof. Tang is a member of the National Medical Professional Degree Graduate Education Steering Committee, the executive director of the China Biomedical Engineering Society, the deputy director of the Chinese Medical Association's Heart Failure Professional Committee. President Tang serves as the chairman of the Hubei Biomedical Engineering Society, and the vice president of the Hubei Provincial Medical Association. Prof. Tang has published more than 220 papers in professional journals at home and abroad, including more than 100 articles in SCI, 21 monographs and editors, and more than 20 key projects of the National Natural Science Foundation.

武汉大学副校长、医学部部长、人民医院院长，心血管内科教授、主任医师、博士生导师。第11届中国医师奖获得者。兼任全国医学专业学位研究生教育指导委员会委员、中国生物医学工程学会常务理事、中国医师协会心力衰竭专业委员会副主任委员、湖北省生物医学工程学会理事长、湖北省医师协会副会长，湖北省医学会心血管病分会常委。在国内外专业期刊发表论文220余篇，其中SCI收录100多篇，主编及参编专著21本，主持国家自然科学基金重点项目等20余项。主持完成省科技进步一等奖2项、参与完成国家和省科技进步奖7项。



## Richard Platt

Professor and Chair, Department of Population Medicine, Harvard Medical School & Director, Harvard Pilgrim Health Care Institute 哈佛医学院人群医学系系主任

Dr. Platt is Professor and Chair of the Department of Population Medicine, and Executive Director of the Harvard Pilgrim Health Care Institute, which is the home of the Department. He leads a 100 person Therapeutics Research and Infectious Diseases Epidemiology group within the Department. He has extensive experience in developing systems and capabilities for using routinely collected electronic health information. He is a member of the Institute of Medicine Roundtable on Value and Science Driven Healthcare and the Association of American Medical Colleges Advisory Panel on Research. He is a principal investigator of the Sentinel program. He is also a co-investigator of the coordinating center of PCORI's National Patient Centered Clinical Research Network. Professor Platt is the co-leader of the NIH Health Care System Research Collaboratory and also leads a CDC Prevention Epicenter.

Richard Platt 教授是哈佛医学院人群医学系主任及教授，哈佛Pilgrim健康保险研究院院长。他带领了一支百人团队来进行传染病流行病学的治疗研究。他在常规收集电子健康信息的系统的研究与功能开发方面拥有丰富的经验。他是医学学会下价值与科学驱动健康系统领导联盟的联合主席，也是美国医学院校研究咨询小组的重要成员之一。他是Sentinel项目的重要研究人员。他还是PCORI国家患者中心临床研究网络协调中心的共同研究员。Platt教授作为美国卫生研究院卫生保健系统研究协作中心的联合领导人，同时也领导了美国疾病预防控制中心下的流行病中心项目(Epicenter)。



**Daniel Tsai 蔡维翰**

Assistant Secretary for MassHealth and Medicaid Director for the Commonwealth  
麻州健保计划（MassHealth）助理部长兼医疗补助计划（Medicaid）主任

Daniel Tsai is the Assistant Secretary for MassHealth and Medicaid Director for the Commonwealth. Tsai was appointed in January 2015 by Governor Charlie Baker to oversee the state's ~\$15 billion Medicaid program, which covers one in four residents in the Commonwealth. In his role, Tsai is responsible for ensuring a robust and sustainable MassHealth program. That includes developing new policies, payment models, and operational processes that improve the way health care is delivered to 1.8 million low-and moderate-income individuals and individuals with disabilities. Before joining HHS, Tsai was a Partner and leader in McKinsey & Company's Healthcare Systems and Services practice. He has significant experience on design and implementation of innovative, state-wide health care payment systems for Medicaid, Medicare and Commercial populations, and has worked closely with multiple state Medicaid programs, private payers, and health services companies.

蔡维翰于2015年1月受马萨诸塞州州长查理·贝克任命，负责监管该州150亿美元的Medicaid补助计划，该计划覆盖了马萨诸塞州四分之一的居民。他负责确保MassHealth健保计划的稳健和可持续发展，包括制定新的政策、支付模式和业务流程，改善为180万中低收入和残疾居民提供医疗服务的方式。在加入美国卫生及公共服务部（HHS）之前，蔡维翰曾任麦肯锡公司医疗系统和业务合伙人 and 高管，在为Medicaid补助计划、Medicare医疗保险计划和商业群体设计以及部署新型全州医疗卫生支付系统方面拥有丰富的经验，并与多个州的Medicaid补助计划、自费群体和医疗服务公司有着密切合作。




**Gordon Moore**

Professor, Population Medicine, Harvard Medical School  
哈佛大学哈佛医学院人群医学系教授

Gordon Moore was one of the founding group that started Harvard Community Health Plan, the parent organization of Harvard Pilgrim insurance, the Atrius medical delivery system, and the Harvard Pilgrim Health Care Institute and Harvard academic department. He served for 15 years becoming Medical Director and Chief Operating Officer before moving on to an academic career of teaching and research. Professor Moore's special area of interest is health care delivery system design and health care management. His most recent publication by Oxford Press was the book, 'Choice Matters: how healthcare consumers make decisions and why managers and clinicians should care'. He is working now on a forthcoming book to be published by Oxford University Press entitled 'High-value Population Health: How to Build a Cost-effective Healthcare System.'

Gordon Moore 是一个创立了诸多部门的集团的成员，这些部门包括哈佛社区健康计划、哈佛Pilgrim健康保险研究院的母公司、Atrius医疗服务系统以及哈佛Pilgrim健康保险研究院和哈佛学术部门。在开始教学和研究的学术职业之前，Moore教授曾担任医疗总监和首席运营官长达15年。Moore教授的特殊兴趣领域是医疗保健服务系统设计和医疗保健管理。最近，他的著作《选择很重要：医疗保健消费者如何做出决定以及管理者和临床医生为何需要予以关注》已由牛津出版社出版。目前他正在撰写的著作《高价值人口人群健康：如何建立一个具有成本效益的医疗体系》也即将付梓成书，由牛津出版社出版。




**Donald M. Berwick**

President Emeritus & Senior Fellow, Institute for Healthcare Improvement  
美国医疗保健改善研究院（IHI）荣休主席

Donald M. Berwick, MD, MPP, FRCP, President Emeritus and Senior Fellow, Institute for Healthcare Improvement, is also former Administrator of the Centers for Medicare & Medicaid Services. Dr. Berwick has served on the faculty of the Harvard Medical School and Harvard School of Public Health, and on the staffs of Boston's Children's Hospital Medical Center, Massachusetts General Hospital, and the Brigham and Women's Hospital. He has also served as Chair of the National Advisory Council of the Agency for Healthcare Research and Quality, and served on President Clinton's Advisory Commission on Consumer Protection and Quality in the Healthcare Industry. Dr. Berwick is the author or co-author of over 160 scientific articles and six books. He currently serves as Lecturer in the Department of Health Care Policy at Harvard Medical School.

Donald M. Berwick, 医学博士、公共政策硕士、伦敦皇家内科医学院院士、医疗保健改善研究院荣休主席及高级研究员，同时也是美国医疗保险和医疗补助服务中心的前任主管。Berwick博士曾在哈佛医学院和哈佛大学公共卫生学院任教，并先后在波士顿儿童医院医疗中心、麻省总医院和布莱根妇女医院工作。他还曾担任医疗保健研究和质量机构国家咨询委员会主席，并在克林顿总统的医疗行业消费者保护和质量咨询委员会任职。Berwick博士被公认为医疗保健质量和改进方面的领导权威。Berwick博士著有或合著有160多篇科学论文及六本著作。他目前在哈佛医学院医疗保健政策系担任讲师。



**Erdan Huang 黄二丹**

Deputy Director, Research Department of Health Service System, Health Development Research Center, National Health Commission of China  
中国国家卫健委卫生发展研究中心卫生服务体系研究部副部长

Erdan Huang works as the Director of the Hospital Management and Reform Research Office of the Health Development Research Center of the National Health Commission of People's Republic of China. As a well-known researcher in the field, Erdan has been invited as a speaker to attend various conferences and gave insightful speeches. Research areas: hospital governance, performance evaluation; tools application: various qualitative research methods; hospital performance and financial data analysis; On June 1, 2018, Erdan was invited to participate in the "The 2nd Mayo Clinic: China Hospital Management Summit in 2018" hosted by Mayo Medical Center, and he delivered a keynote speech in Shanghai.

黄二丹就职于国家卫健委卫生发展研究中心医院管理与改革研究室主任一职。作为行业享有盛名研究者，黄二丹多次受邀作为嘉宾出席各类大会，并发表了主旨演讲。研究领域：医院治理，绩效评价；使用工具：各类定性研究方法；医院绩效与财务数据分析；2018年06月01日,黄二丹受邀参加了由梅奥医学中心主办的《2018第二届梅奥诊所中国医院管理峰会》。



**Jianqin Gu 顾建钦**

Vice President, Henan Provincial People's Hospital, China  
中国河南省人民医院副院长

Dr. Jianqin Gu, the current Secretary and Chief Physician, Chairman of Henan Provincial People's Hospital; Visiting Professor and Professor at Shanghai Jiao Tong University, Huazhong University of Science and Technology, Central South University for Nationalities, Henan University, Zhengzhou University and Wuhan University of Science and Technology.

顾建钦博士现任河南省人民医院党委书记，主任医师，上海交通大学、华中科技大学、中南民族大学、河南大学、郑州大学、武汉科技大学等多所大学客座教授和博、硕士生导师。




**Ezra F. Vogel 傅高义**

Henry Ford II Professor of the Social Sciences Emeritus, Harvard University  
哈佛大学社会科学荣休教授，东亚问题知名学者

Ezra F. Vogel received the Harvard Graduate School Centennial Medal for contribution to society. He was the only Western scholar to receive the 2013 China special Book Award from the China State Administration of Publication, Press, Radio, Film and Television.

傅高义教授是哈佛大学社会科学荣休教授。1972年至1977年，傅高义教授接替John Fairbank 成为哈佛东亚研究中心第二任主任，1977年至1980年，担任东亚研究理事会主席。1980年至1987年，他在国际事务中心担任美日关系项目的负责人，1987年起担任名誉主任。1995年至1999年，他担任费正清研究中心，1997年至1999年，担任亚洲中心第一任主任。2001年，他还担任亚洲基金会东亚政策建议工作组的副主任。傅高义教授获得了十个荣誉学位。他于1998年获得日本社会奖，还被选为美国艺术和科学院院士。2008年，他因对社会的贡献获得哈佛研究生院的百年勋章。他是唯一一位获得中国国家新闻出版广电总局颁发的2013年中国特别图书奖。



**William Haseltine**

Chairman, U.S.-China Health Summit 中美健康峰会主席  
Chairman and President, Access Health International Access Health主席

Please turn to page15 to see speaker's bio

讲者简介详见第15页



**Mark Wu 伍人英**

Henry L. Stimson Professor, Harvard Law School  
哈佛大学法学院Henry L. Stimson教授

Mark Wu is an Assistant Professor of Law at Harvard Law School and a Director of the Berkman Klein Center. His work focuses on international trade and international intellectual property matters. Prior to joining HLS the faculty in 2010, Mark Wu was an Academic Fellow at Columbia Law School and a law clerk to Judge Pierre N. Leval of the U.S. Court of Appeals for the Second Circuit. He has served as the Director for Intellectual Property in the Office of the U.S. Trade Representative, where he led negotiations on the IP chapters of various free trade agreements. In addition, he worked as an engagement manager for McKinsey & Co., as an economist and operations officer for the World Bank in China, and as an economist for the United Nations Development Programme in Namibia.

Mark Wu是哈佛大学法学院的助理教授，也是伯克曼克莱因中心的主任。他的工作重点是国际贸易和国际知识产权问题。在2010年加入哈佛法学院之前，Mark Wu 是哥伦比亚大学法学院的学术研究员，也是美国第二巡回上诉法院法官Pierre N. Leval的法律助理。他曾担任美国贸易代表办公室知识产权局局长，领导多项自由贸易协定的知识产权章节谈判。此外，他还曾担任麦肯锡公司的聘任经理，中国世界银行的经济学家和运营官，以及纳米比亚联合国开发计划署的经济学家。



**James Frank Wharam**

Chief, Division of Health Policy & Insurance, Department of Population Medicine, Harvard Medical School  
哈佛大学医学院人群医学系医疗政策与保险部主任

Frank Wharam, MB, BCh, BAO, MPH, is an Associate Professor and a General Internist at Harvard Medical School and Harvard Pilgrim Health Care Institute. He is director of the Division of Health Policy and Insurance Research in the Department of Population Medicine (DPM) and site director of DPM's Harvard Medical School General Internal Medicine fellowship. Dr. Wharam has expertise in analysis of large databases, and understanding how medical care can be accurately assessed using health insurance claims data. He leads or has led seven major projects examining effects of high-deductible health plans (HDHPs) on appropriate health care and has published early studies of modern HDHPs. Dr. Wharam has also been Principal Investigator and co-investigator of an examination of the impact of a regional Massachusetts HDHP on a spectrum of outcomes.

Wharam是哈佛医学院和哈佛Pilgrim健康保险研究院的副教授和内科医生。他是人群医学系（DPM）卫生政策和保险研究部主任，也是DPM哈佛医学院普通内科专科培训的主任。Wharam博士在大型数据库分析，健康保险福利设计细节方面，以及如何准确使用健康保险索赔数据进行评估医疗健康方面有深厚造诣。他领导过七个重大项目，研究高抵扣额健康保险（HDHPs）对合适医疗健康的影响，并发表了现代HDHP的早期研究结果。Wharam博士还担任首席研究员和联合研究员，负责检查马萨诸塞州地区HDHP对一系列医疗结果的影响。





**Shaoping Deng 邓绍平**

President, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital  
四川省医学科学院、四川省人民医院院长

Dr. Shaoping Deng is currently the President of Sichuan Provincial People’s Hospital. He is MD and a Chief Physician, Professor, and one of the first members of “Hundred Experts Program” in Sichuan Province. Dr. Deng is also the Director of the Institute of Organ Transplantation of Sichuan Provincial People’s Hospital and a transplant surgery researcher at Massachusetts General Hospital of Harvard Medical School. Dr. Deng’s team conducted both basic and pre-clinical research focusing on xenotransplantation, islet transplantation, and induction of immunotolerance, collaborating with researchers at the Harvard Medical School Transplant Center. His work is cutting-edge in the world. Dr. Deng has more than 10 research projects, including the ones funded by US National Institute of Health and National Natural Science Foundation of China. Dr. Deng has three patents declared both domestically and internationally.

邓绍平博士，现任四川省人民医院院长。医学博士、主任医师、教授、博士生导师，四川省首批海外“百人计划”引进人才。兼任四川省人民医院器官移植研究所所长、哈佛大学医学院麻省总医院移植外科副研究员。邓绍平带领的科研人员与哈佛大学医学院移植中心合作，在异种移植、胰岛移植、诱导免疫耐受多个领域开展基础及临床前研究，这些工作均处于国际先进、国内领先的地位。目前邓博士参与或主持的科研资助项目共10余个，包括资助课题和国家自然科学基金等。申报国内外发明专利3项。在诱导免疫耐受方面的研究取得了突出成绩。



**Mark Fendrick**

Director, Value-Based Insurance Design (V-BID) Center, University of Michigan  
密歇根大学基于价值保险设计中心(V-BID)主任

Dr. Fendrick is a graduate of Harvard Medical School in Boston, and he completed his internal medicine residency at the University of Pennsylvania Medical Center in Philadelphia. Dr. Fendrick conceptualized and coined the term Value-Based Insurance Design (V-BID) and currently directs the V-BID Center at the University of Michigan. Dr. Fendrick’s research focuses on how clinician payment and consumer engagement initiatives impact access to care, quality of care, and healthcare costs. Dr. Fendrick is an elected member of the National Academy of Medicine (formerly IOM), serves on the Medicare Coverage Advisory Committee, and has been invited to present testimony before the U.S. Senate Committee on Health, Education, Labor and Pensions, the U.S. House of Representatives Ways and Means Subcommittee on Health, and the U.S. Senate Committee on Armed Services Subcommittee on Personnel.

Fendrick博士毕业于波士顿哈佛医学院。他在宾夕法尼亚大学医学院完成专科医生培训，并在宾夕法尼亚大学医学中心和费城退伍军人事务医疗中心完成了内科专科医生培训。Fendrick博士概念化并创造了价值保险设计（V-BID）这一术语。他的研究重点包括临床医生支付和消费者参与主动性如何影响医疗的可及性，质量，和成本。Fendrick博士是美国国家医学院（前身为IOM）的当选成员，在医疗保险覆盖咨询委员会任职，并受美国参议院邀请在健康，教育，劳工和养老金，美国众议员的筹款委员会健康分会等听证会上提供过证词。



**Michael Sherman**

Chief Medical Officer, Harvard Pilgrim Health Care  
哈佛Pilgrim健康保险研究院首席医疗官兼高级副总

Dr. Michael Sherman serves as chief medical officer and senior vice president for health services for Harvard Pilgrim Health Care. A pioneer in developing outcomes-based payment agreements with pharmaceutical companies, and he recently signed the first value-based agreement for a gene therapy used to treat a form of blindness. Dr. Sherman serves as chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and on the Advisory Board of the Institute for Clinical and Economic Review (ICER). He also is the current chair for AHIP’s CMO Leadership Council, comprising chief medical officers from health plans throughout the United States, and serves on the board of directors for the Personalized Medicine Coalition. Dr. Sherman held leadership roles at Humana, UnitedHealth Group, and Thomson Medstat (now IBM Truven).

Michael Sherman 博士是哈佛Pilgrim健康保险研究院的首席医疗官兼高级副总裁。他率先倡导与制药公司制定以治疗结局为导向的支付协议，最近他还签署了首例以价值为导向的治疗失明的基因治疗协议。Sherman博士是哈佛Pilgrim健康保险研究院的管理委员会主席，也是临床与经济评论研究所（ICER）的咨询委员会的一员。他还是美国健康保险计划的首席医疗官和领导委员会的现任主席。Sherman博士曾在Humana、UnitedHealth Group 和 Thomson Medstat公司（现IBM 旗下Truven公司）担任领导职务。



**Yong Xu 徐勇**

President, Shenzhen People’s Hospital, China  
深圳市人民医院书记

Yong Xu is currently the chairman of Shenzhen People’s Hospital. Part-time professor, MD, with post-doctoral work experience. He is currently the vice president of the Shenzhen Hospital Management Association and the chairman of the Operation and Evaluation Committee, the chairman of the Shenzhen Medical Association Integrated Medicine Committee, the editor of the China Hospital Management Journal and the Journal of Modern Hospital Management. His research interests include hospital management, hospital performance appraisal performance allocation, hospital/discipline/doctor medical service capacity assessment, DRG grouping principles and applications, disease classification and diagnosis and treatment complexity, medical resource allocation and medical service payment.

徐勇现任深圳市人民医院党委书记。兼职教授，医学博士，博士后工作经历现任深圳市医院管理者协会副会长暨运营与评价专委会主委、深圳市医学会整合医学专业委员会主任委员、《中国医院管理杂志》、《现代医院管理杂志》编委。研究方向为医院管理、医院绩效考核/绩效分配、医院/学科/医生医疗服务能力评估、DRG分组原理及应用、疾病分类及诊疗复杂度研究、医疗资源分配与医疗服务支付等。



### David Khougazian

Head of Specialty Care for China and Emerging Market, Sanofi  
赛诺菲中国与新兴市场孤儿药与特殊药品总负责人

David Khougazian is the Global Head for Sanofi Genzyme China & Emerging Markets and is responsible for driving Sanofi Genzyme Specialty Care operations in China and Emerging Markets. David is also the grand architect of Sanofi's Partnerships for Health – a program, which offers a win win approach to achieve government's ambitions and to create a healthy & attractive market for the life sciences industry in Emerging Markets. Up until March 2019, David was heading the Eurasia & Middle East Region for Sanofi, where multiple specialty care products have been launched. Previously, David was the CEO of Sanofi Pasteur MSD, the leading vaccines company in Europe. David has also held a series of leadership roles since joining Sanofi in 1997, including Chief of Staff to the Sanofi CEO, where he led various global projects, or General Manager Positions in Europe. David started his career in banking as fund manager in HSBC.

David Khougazian 是赛诺菲健赞（中国）和新兴市场的全球负责人，直至2019年3月，David一直担任赛诺菲欧亚及中东地区的主管，期间他推出了多种专业护理产品。此前，David曾担任欧洲领先的疫苗公司赛诺菲巴斯德默沙东(Sanofi Pasteur MSD)的首席执行官。自1997年加入赛诺菲以来，David担任过一系列领导职务，包括负责领导各种全球项目的办公室主任及赛诺菲首席执行官，以及欧洲的总经理职位。David的职业生涯始于汇丰银行的基金经理。



### Aiping Yang 杨爱平

Director, Center for Capacity Building & Continue Education, National Health Commission of China  
中国国家卫健委能力建设与继续教育中心主任

Aiping Yang, currently holds the position of the director of The Office of National Health Commission Capacity Building and Continuing Education. He graduated from Sichuan University in July 1988 with a major in Journalism, and has served several positions at the Chinese Population Newspaper as editor, reporter, assistant director, chief editor, deputy director of the editor-in-chief. He was also the Deputy Editor of China Population Newspaper in 2004; and has become the Assistant Director of The National Population and Family Planning Talent Exchange Center since June of 2011. In December 2014, He started his position as the Director of The Family Planning Center for Capacity Building and Continuing Education.

杨爱平现任国家卫生健康委能力建设和继续教育中心主任。他于1988年7月毕业于四川大学新闻系，历任中国人口报社编辑、记者、总编室副主任、主任、总编辑助理，2004年2月任中国人口报社副总编辑，2011年6月起任国家人口计生委人才交流中心副主任（主持工作），2014年12月任国家卫生计生委能力建设和继续教育中心主任。



### Qingyu Kong 孔晴宇

Vice President, Beijing Anzhen Hospital, Capital Medical University  
首都医科大学北京安贞医院副院长

Dr. Kong has been engaged in the cardiovascular surgery for 31 years and has accumulated extensive clinical experience. Dr. Kong's expertise includes: surgical treatment of coronary artery disease, Valvular heart disease, adult congenital heart disease, and surgical treatment of cardiovascular disease. Dr. Kong was the Captain of the 23rd batch of Chinese medical team assisting Guinea. From 1992 to 1993, Dr. Kong was the Visiting Researcher at the Department of Cardiac Surgery of San Donato Hospital, Milan, Italy.

孔晴宇先生从事心脏大血管外科临床工作31年，积累了丰富的临床经验。业务专长：冠心病、心脏瓣膜疾病、成人先心病、心脏大血管疾病的外科治疗。曾是中国第23批援几内亚医疗队队长。1992—1993年意大利米兰圣多纳托医院心脏外科访问学者。



### Mei Xu 徐梅

President, Yunnan Richland Hospital, Kunming, Yunnan  
云南瑞奇德医院院长

Mei Xu is the President, chief physician and psychologist of Yunnan Richland Hospital. Ms. Xu is a national public nutritionist, health manager, American functional medicine physician, and the chief medical expert of the Holistic Medicine Research Center of the Chinese Academy of Sciences Health Management Alliance. In 2006, funded by overseas investment, she established the Richland Hospital (JCI accredited in 2015). In October 2017, she became the chair of first Clinical Holistic Medicine Management Committee in China. Ms. Xu was invited to TED Talks and shared a keynote speech titled "Looking for the Causes. Holistic Medicine Practices". She introduced the complementation of traditional Chinese medicine (TCM) Yi-ology and modern medicine, and the value of I Ching in diseases diagnosis and treatment. She also shared her new holistic medicine theory of "Chinese essence and Western utility" as well as her clinical practice.

徐梅，云南瑞奇德医院院长、主任医师和心理医生，是国家公共营养师和健康管理师、美国功能医学师，同时还是中科院健康管理联盟整体医学研究中心首席医学专家。她于2006年获得中国第一笔境外医疗投资，由此创建了瑞奇德医院（2015年获得JCI认证）。2017年10月她成为中国第一个临床整体医疗专业委员会主任委员。徐女士曾受邀登上TED演讲台，分享了题为《寻找病因.整体医疗实践》的主旨演讲，介绍了中医易学与现代医学的互补以及易经在诊疗疾病的价值，并分享其全新“中医为体、西学为用”整体医疗理论及临床实践。该模式治愈了大量传统医学模式下无法治愈的疾病。



**Tao Hong 洪涛**

Vice President, 1st Teaching Hospital, Nanchang University  
南昌大学第一附属医院副院长

Dr. Hong Tao is a doctoral supervisor, chief physician and national second-level professor. He is Vice President of the First Affiliated Hospital of Nanchang University, specializes in the surgical treatment of brain tumors and cerebrovascular diseases, especially in endoscopic skull base surgery, moyamoya disease and vascular bypass of complex aneurysms, and in the surgical treatment of other complex intracranial lesions.

洪涛,博士生导师，主任医师，国家二级教授，现任南昌大学第一附属医院副院长，擅长脑肿瘤、脑血管病的外科治疗，特别在内镜颅底外科、烟雾病及复杂动脉瘤颅内外血管搭桥，颅内其他复杂病变的外科治疗方面有较深造诣。




**Marc-David Munk**

Former Chief Medical Officer, CVS Minute Clinic  
CVS Minute Clinic前首席医疗官

As the Chief Medical Officer for CVS MinuteClinic™, Munk oversees patient care strategies with a focus on helping ensure that MinuteClinic® continues to provide high-quality and accessible clinical care to patients. As Senior Vice President and Associate Chief Medical Officer for CVS Health, Munk is guiding development of innovative strategic programming and expanded health care services across the CVS Health enterprise. Prior to joining CVS Health, Munk held leadership positions at the University of New Mexico Health System and the University of Pittsburgh Medical Center, and served as Chief Medical Officer of several regional provider organizations. Munk holds a medical degree from Jefferson Medical College, a Master of Public Health (MPH) from Boston University, and a Master of Science in Health Care Management (MHCM) from Harvard University.

作为CVS MinuteClinic™ 的首席医疗官，Munk监管患者护理策略，确保MinuteClinic®继续为患者提供高质量和可及的临床护理。作为CVSHealth的高级副总裁兼副首席医疗官，Munk指导CVS Health企业的创新战略和扩展医疗健康服务。在加入CVS Health之前，Munk在新墨西哥大学卫生系统和匹兹堡大学医学中心担任领导职务，并担任多个地区医疗组织的首席医疗官。Munk拥有杰斐逊医学院的医学学位，波士顿大学的公共卫生硕士学位（MPH）和哈佛大学的医疗健康管理硕士学位（MHCM）。



**Arlene Bierman**

Director of Center for Evidence and Practice Improvement (CEPI), Agency for Healthcare Research and Quality (AHRQ), U.S. DHHS  
美国卫生及公共服务部医疗研究与质量局(AHRQ)证据与实践改进中心主任

Arlene S. Bierman, M.D., M.S., leads the work of CEPI. Dr. Bierman is a general internist, geriatrician, and health services researcher, whose work has focused on improving access, quality, and outcomes of health care for older adults with chronic illness in disadvantaged populations. Dr. Bierman has served on many advisory committees, including the Geriatric Measurement Advisory Panel of the National Committee for Quality Assurance and the boards of Health Quality Ontario and the National Center of Excellence National Initiative for Care of the Elderly (NICE). She received her MD degree from the University of North Carolina School of Medicine in Chapel Hill.

Bierman博士是一名内科医生，老年病学家和健康服务研究员，并领导证据与实践改进中心（CEPI）的工作。她的工作重点是改善弱势群体中患有慢性病老年人的医疗的可及性，质量和结果。Bierman博士曾在许多顾问委员会任职，包括国家质量保证委员会的老年病评估顾问小组和安大略省健康质量委员会，以及创新老年人护理中心（NICE）国家卓越项目。她在北卡罗来纳大学医学院获得了医学博士学位。




**Christine Lu**

Associate Professor & Co-director, PRecisiOn Medicine Translational Research (PROMoTeR) Center, Department of Population Medicine, HMS & HPHCI  
哈佛医学院人群医学系精准医学研究中心主任及副教授

Christine Lu, MSc, Ph.D, co-directs the PRecisiOn Medicine Translational Research (PROMoTeR) Center. She is a pharmacist, health policy scientist and pharmacoepidemiologist. After receiving an MSc (Biopharmaceuticals) and a PhD in Clinical Pharmacology from the University of New South Wales, Australia, Dr. Lu completed her post-doctoral training at Harvard Medical School. Dr. Lu leads the precision medicine & policy, and precision medicine oncology portfolios for the DPM. Her research focuses on the policy, legal, ethical, economic and societal issues of precision medicine, which have substantial impacts on the coverage and reimbursement and clinical integration of genomic testing and sequencing. She is Co-Principal Investigator of Genomics-based Technologies: Access and Reimbursement Issues. Dr. Lu co-leads the Genetic and Molecular Tests Data Workgroup for the Cancer Research Network.

Christine Lu 是PRecisiOn医学转化研究（PROMoTeR）中心的联合主任，药剂师，健康政策科学家和药物流行病学家，在获得澳大利亚新南威尔士大学的临床药理学硕士（生物制药）和博士学位后，Lu博士在哈佛医学院完成了博士后培训。Lu博士领导精准医学及其相关政策，以及人群医学系的精准医学肿瘤学组合。她的研究重点是精准医学的政策，法律，伦理，经济和社会问题。这些问题对基因组测试和测序的覆盖率、报销以及临床整合有重大影响。她是基因组学技术的联合首席研究员，主导访问和报销问题。Lu博士共同领导癌症研究网络的遗传和分子测试数据工作组。她还进行研究以评估基因组测试和测序的实际效用，包括基于价值的合同的影响。





**Joe Kimura**

Chief Medical Officer, Atrius Health

Atrius Health 社区医疗联盟首席医疗官首席医疗官

Joe Kimura, MD MPH is Chief Medical Officer of Atrius Health and an internist at Harvard Vanguard Medical Associates, a medical practice of Atrius Health. He has broad experience leading ambulatory care delivery system improvements with specialty expertise in clinical informatics and healthcare data analytics. Since 2014, he has served as co-chair of the ONC HIT federal advisory workgroup on Advanced Health Models and Meaningful Use. Dr. Kimura has been nationally recognized as a Top 25 Clinical Informaticists by Modern Healthcare in 2012 and one of thirty leading CMIO experts by Health Data Management in 2016. Dr. Kimura was an undergraduate at Stanford University, received his medical degree from Washington University, and his public health degree from Harvard University.

Joe Kimura, MD, MPH, 是Atrius Health的首席医疗官，也是Atrius Health的医疗实践点–哈佛先锋医学协会的内科医生。Kimura博士在临床信息学和医疗数据分析方面拥有专业知识。他曾在Atrius Health担任分析和报告系统医疗总监以及质量测评医疗总监。自2014年以来，他一直担任美国卫生信息技术协调员办公室联邦咨询工作组的联合主席。Kimura博士于2012年被《现代医疗》杂志评为25位顶尖临床信息学家之一，并于2016年被《健康数据管理》杂志评为30位首席医疗信息官专家之一。Kimura博士本科毕业于斯坦福大学，随后获得了华盛顿大学的医学博士学位及哈佛大学的公共卫生学硕士学位。他在旧金山的加州大学完成初级保健内科住院医师培训，并在哈佛医学院的门诊护理和预防部门完成医疗服务研究员工作。在结束麻省理工斯隆管理学院的高级管理课程后，Kimura博士获得了管理、创新和技术方面的资历认证。



**Alfred Demaria**

Former State Epidemiologist for Massachusetts and former Medical Director of the Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health

麻州公共卫生署传染病局前医学主任、麻州首席流行病学家

Dr. DeMaria is a Medical and Laboratory Consultant at the Massachusetts Department of Public Health where he previously served as Medical Director of the Bureau of Infectious Disease and Laboratory Sciences, and for many years, State Epidemiologist for Massachusetts. Dr. DeMaria is a Fellow of the Infectious Diseases Society of America and of the Society for Healthcare Epidemiology of America, serves on multiple committees of the Massachusetts Medical Society, and is Secretary of the Board of Directors of The Public Museum. Currently he serves as the President of the Massachusetts Infectious Diseases Society, and is a past president of the Council of State and Territorial Epidemiologists and the Northeast Branch of the American Society for Microbiology.

Bierman博士目前担任马萨诸塞州公共卫生的医疗和实验室顾问。此前，他在该部门的传染病预防应对和服务局担任医疗主任。在1989年加入公共卫生部之前，他是私人执业的传染病顾问，再之前他在麦克斯韦芬兰传染病实验室和传染病科、波士顿市医院和波士顿大学医学院工作。DeMaria博士是美国传染病学会以及马萨诸塞州医学会和美国医疗健康流行病学协会的会员，并且担任马萨诸塞州医学会的委员以及公共卫生博物馆的董事会秘书。他目前担任马萨诸塞州传染病学会的主席，之前曾担任州与地方流行病学家委员会和美国东北微生物学家学会的主席。



**Mark Davis**

Vice President of Brigham Health International, Executive Director of Business Development and Strategic Initiatives, Brigham Health

布莱根健康国际副总监；布莱根健康业务发展与战略行动执行总监

Mark A. Davis is the Vice President of Brigham Health International and the Executive Director of Business Development and Strategic Initiatives for Brigham Health. Dr. Davis is also an Associate Professor of Emergency Medicine at Harvard Medical School. He is responsible for identifying, negotiating, and implementing national and international business opportunities for Brigham Health, the parent organization of Brigham and Women's Hospital. Creating and working closely with cross-functional teams, he provides operational oversight of strategic collaborations that align with the mission of Brigham Health and benefit patients and partner institutions. Previously, Dr. Davis served as Medical Director, Network Development for Brigham and Women's Hospital, concentrating on advancing local and regional relationships.

Mark Davis 是布莱根健康国际副总监，同时兼任布莱根健康业务发展与战略行动执行总监。在学科上，Davis博士同时也担任哈佛医学院急诊医学的副教授。多年以来，他致力于为布莱根医疗健康系统（布莱根妇女医院的母系统）探索、沟通、落地美国本土及世界各地的商务发展机会，创建并与多个多元化团队紧密联合，前瞻性的运营策略合作性伙伴关系来实际落实布莱根医疗健康系统的使命，造福更多患者及众多合作机构。在此之前，Davis博士还曾经在布莱根妇女医院担任在地关系发展医疗总监，致力于完善当地及地区性医院关系建设。



**Jing Ma 马晶**

President & Secretary-General, U.S.-China Health Summit

中美健康峰会主席兼秘书长

Please turn to page 15 to see speaker's bio

讲者简介详见第15页



### A LEADER IN SPECIALTY CARE

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, oncology, immunology, and rare blood disorders. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Our ambition is to be the industry leader in specialty care. We currently provide more than 25 treatments to patients globally, with many potential new therapies in development.

### OUR APPROACH

Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Across each of the therapeutic areas where we focus, we work to identify and address unmet medical needs where patients do not have adequate treatment options. Our commitment to scientific discovery and innovation is foundational to our ability to serve our existing patient populations and offer hope to underserved patient populations in the future.

### SCIENCE

Sanofi has a strong pipeline with a significant portion of its R&D spending concentrated on specialty care. Sanofi Genzyme's presence in Cambridge, Massachusetts — the international center for biotechnology and innovation — has helped Sanofi expand its capacity to collaborate with world-class scientists in universities, research hospitals, and other companies to accelerate treatment development.

### RESPONSIBILITY

Our dedication to patients extends beyond the development of medicines. We support access to treatment through humanitarian programs to help ensure that appropriate treatment reaches all those who need it.

### CHINA

In 1982, Sanofi opened an office in China as one of the first multinational corporations to support China's opening up and reform. Sanofi China has a diversified business that ranges from pharmaceuticals and human vaccines to consumer healthcare. We have 12 offices, four R&D sites and three production sites in China. With over 9,000 employees across the country, Sanofi is committed to introducing innovative medicines and vaccines faster in China, and leading digital innovations to serve the broadest base of the Chinese people.



The company is known as Merck in the United States and Canada. Everywhere else, we are known as MSD. Merck & Co., Inc. is the legal name and is listed on the New York Stock Exchange under the symbol "MRK." Merck is an innovative, global healthcare leader that is committed to improving health and wellbeing around the world. Our core product categories include diabetes, cancer, vaccines and hospital acute care. We continue to focus our research on conditions that represent some of today's most significant health challenges like cancer, HIV, HPV, hepatitis C, cardio-metabolic disease, antibiotic-resistant infection and Alzheimer's disease, and we are on the front lines in the fight against emerging global pandemics, such as Ebola. We also devote extensive time and energy to increasing access to medicines and vaccines through farreaching programs that donate and deliver our products to the people who need them. At Merck, we're applying our global reach, financial strength and scientific excellence to do more of what we're passionate about: improving health and improving lives.



BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit [bd.com](http://bd.com).



Harvard Pilgrim and its family of companies provide health benefit plans, programs and services to more than 3 million customers in New England and beyond. A leading not-for-profit health services company, we guide our members – and the communities we serve – to better health.

Founded by doctors 50 years ago, we're building on our legacy. In partnership with our expansive network of doctors and hospitals, we're improving health outcomes and lowering costs through clinical quality and innovative care management.



Xian Janssen Pharmaceutical Ltd. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. It is one of China's largest pharmaceutical companies and among the earliest multinational pharmaceutical companies to enter China simultaneous with the opening-up of China's economy. Since its establishment in 1985, Xian Janssen has been committed to providing Chinese patients with high-quality, innovative products that fulfill unmet medical needs in psychiatry, neurology, oncology, immunology, and gastrointestinal, fungal and infectious diseases. Based on the company's Credo and spirit of caring, Xian Janssen has been an active corporate citizen, successfully implementing more than 50 cooperative projects in the areas of medicine, public health, medical R&D, and corporate social responsibility.



Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company has a comprehensive range of medical devices and is one of the largest providers in North America. By 2017, the total number of employees has exceeded 36,000, and the annual sales revenue is about 6.3 billion euros. It is one of the top ten generic pharmaceutical companies in the world. Main business areas: clinical nutrition therapy, infusion therapy, intravenous injection, medical devices and biomimetic drugs. There are 5 production bases and 3 R&D centers in China. For many years, staff members have been organized to carry out various public welfare activities such as blood donation, disaster relief and so on. With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.



Roche is the world's leading biotech company with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

The Roche Group, founded in 1896, is active in over 150 countries and employed more than 94,000 people worldwide. Thirty-one medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarial and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry 10 years in a row by the Dow Jones Sustainability Indices (DJSI). In 2018, Roche invested 11.2 billion USD in R&D and posted sales of 57.7 billion USD. Genentech, in the United States, is a wholly owned member of the Roche Group.





Clark+Elbing LLP is a top-tier intellectual property (IP) law firm that represents clients at the forefront of scientific discovery and technological innovation. From universities, medical centers, and companies of all sizes to the investors who back them, we represent leaders in their respective fields. Our practice encompasses IP in the areas of life science, chemistry, devices, and diagnostics. To learn more about us, please visit [www.clarkelbing.com](http://www.clarkelbing.com).




Since 2015, Infervision has been devoted to bring the most advanced technologies to the healthcare space. Along all these years, Infervision has used deep learning technologies to analyze medical imaging data of different modalities such as DR, CT, and MRI, providing highly precise and useful tools to the medical professionals, alleviating the high workload pressure and empowering healthcare professionals with more capabilities.



Founded in 1995 and by Mr. Qian Xinzong, former Minister of Health of the People's Republic of China, Chinese Aging Well Association (CAWA) is China's first national-level association to focus on the population aging and developments of the senior healthcare industry. In the past 20 years, the Association has established dozens of specialized and working committees, covering the healthcare, enabling environment, retirement products and investments, recreation and entertainment for the elderly. The chairs and members of the committees are top experts from the Class III Level A hospitals in the country and leaders of the industry, and some other former national leaders also join the Association as senior advisors. As a result of its continuous endeavor, CAWA has become an important, well-recognized and reputable player in the industry.



Beijing Medical and Health Foundation (the Foundation) is a non-profit organization for public welfare registered with Beijing Civil Service Commission. Its business activities focus on soliciting, managing and utilizing social funds to sponsor medical and public health related science research, academics exchange, training and education, international communication, promotion of clinical usage of mature research results, infrastructure development, construction of medical specialties and cultivation of human resources. The mission of the Foundation is to improve the medical and public health condition, improve the research and development on medicine in China, and encouraging using social funds for medical related public welfare in China. In the meantime, various types of funds have been set up within the Foundation which includes Medical R&D Fund, Medical Academic Exchange Fund, Medical International Communication Fund, Medical Training and Education Fund.



BOARD MEMBERS 理事会成员

- **Barry Bloom (Founding Chairman), PhD,**  
Distinguished University Service Professor, Joan L. and Julius H. Jacobson Professor of Public Health, Harvard University, USA
- **Yuanli Liu (Founder) PhD,**  
Professor and Dean of Peking Union School of Public Health (PUSPH); President, China Aging Well Association, China
- **Jing Ma (Co-founder; President & Secretary General), MD, PhD**  
Director, China Program for Health Innovation and Transformation, Department of Population Medicine, Harvard Medical School, USA
- **William Haseltine (Chairman), PhD,**  
Founder and Chairman, ACCESS Health International, USA
- **Lan Xue, PhD,**  
Cheung Kong Chair Professor and Dean of Schwarzman College, Tsinghua University, Beijing, China
- **Olivia Ho. Cheng (Treasurer),**  
Board Member, Tufts Medical Center; CEO, Aurora Healthcare Corp, USA
- **Feng Deng,**  
Founder and CEO, Northern Light Venture Capital, Beijing, China
- **Steven Wu, MD, FASN,**  
Director of Interventional Nephrology, Massachusetts General Hospital, Harvard Medical School, USA
- **Ligang Zhang,**  
Founder, Chairman & CEO, iKang Health, Beijing, China

OPERATION COMMITTEE 筹备委员会

U.S. Team 美国团队	China Team 中国团队
Clement Dai 戴华	Gongwu Ding 丁工物
Hongkai He 何鸿恺	Shiyang Liu 刘诗洋
Jason Liu 刘大江	Lihong Ma 马立红
Yulin Liu 刘育琳	Rui Su 苏蕊
David Mou	Yinuo Wu 吴一诺
Susan Pan 潘淑娟	Qi (Jessie) Xie 谢麒
Yaqing (Tyler) Tang 汤亚清	Yingjie Zhang 张颖洁
Pei Tong 童佩	Shaodong Zhong 宗少东
Sally Wang Liang 梁王渊恒	
Guangyu Zhou 周广宇	
Juan (Carol) Zhou 周涓	
Yun Zhu 朱筠	

VOLUNTEERS 志愿者

Qian Bi 毕茜	Lechen Qian 钱乐琛
Zhuoran Cao 曹卓冉	Lei Shen 沈蕾
Xiaoli Chen 陈小丽	Yue Wang 王悦
Yutong Chen 陈禹彤	Tingting Xu 徐婷婷
Xue Cui 崔雪	Hongjin Xu 徐宏进
Jinglin Fu 傅婧琳	Yuchen Yang 杨宇晨
Yunshu Huang 黄筠舒	Hailing Yang 杨海凌
Nancy Jen 任娜娜	Chaoqun Yin 尹超群
Xinran Li 李欣然	Ruibo Zhang 张睿博
Yifei Lin 林逸飞	Lida Zhang 张立达
Jingyi Liu 刘竟伊	Hepu Zhang 张和浦
Luwei Liu 刘露蔚	Zhuoya Zhang 张卓雅
Sijia Ma 马斯葭	Qiaojia Zhang 张巧佳
Wenlan Mao 毛文澜	Kaihang Zhao 赵恺航
Kristin Qi 祁亚男	Ziqi Zheng 郑子琦



**U.S.-CHINA  
HEALTH SUMMIT**  
中美健康峰会

**Boston Office**

Address: 1 Broadway, 14th Fl 005 Cambridge, MA 02142  
Email: info@uschinahealthsummit.org  
Contact: Juan Zhou  
Mobile: (01)617-335-0692

**北京办公室**

地址: 北京东城区西总布胡同46号C座7层 (100005)  
电话: (86)10-8529-3038  
电子邮箱: info@health-summit.org  
联系人: 蒋锋  
手机&微信号: (86)139-1028-6931

[www.uschinahealthsummit.org](http://www.uschinahealthsummit.org)



@USChinaHealth



U.S.-China Health Summit



@uschinahealthsummit



中美健康峰会